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ABSTRACT 
 
Laboratory tests are a primary resource for diagnosing patient diseases. However, 
physicians often make decisions based on a single laboratory result and have a limited 
perspective of the role of commonly-measured parameters in enhancing the diagnostic process. 
By providing a dynamic patient profile, the diagnosis could be more accurate and timely, 
allowing physicians to anticipate changes in the recovery trajectory and intervene more 
effectively.  
The assessment and monitoring of the circulatory system is essential for patients in 
intensive care units (ICU). One component of this system is the platelet count, which is used in 
assessing blood clotting. However, platelet counts represent a dynamic equilibrium of many 
simultaneous processes, including altered capillary permeability, inflammatory cascades (sepsis), 
and the coagulation process. To characterize the value of dynamic changes in platelet count, 
analytical methods are applied to datasets of critically-ill patients in (1) a homogeneous 
population of ICU cardiac surgery patients and (2) a heterogeneous group of ICU patients with 
different conditions and several hospital admissions.   
The objective of this study was to develop a methodology to anticipate adverse events 
using metrics that capture dynamic changes of platelet counts in a homogeneous population, then 
redefine the methodology for a more heterogeneous and complex dataset. The methodology was 
extended to analyze other important physiological parameters of the circulatory system (i.e., 
ix 
 
calcium, albumin, anion gap, and total carbon dioxide).  Finally, the methodology was applied to 
simultaneously analyze some parameters enhancing the predictive power of various models.  
This methodology assesses dynamic changes of clinical parameters for a heterogeneous 
population of ICU patients, defining rates of change determined by multiple point regression and 
by the simpler fixed time parameter value ratios at specific time intervals. Both metrics provide 
prognostic information, differentiating survivors from non-survivors and have demonstrated 
being more predictive than complex metrics and risk assessment scores with greater 
dimensionality.   
The goal was to determine a minimal set of biomarkers that would better assist care 
providers in assessing the risk of complications, allowing them alterations in the management of 
patients. These metrics should be simple and their implementation would be feasible in any 
environment and under uncertain conditions of the specific diagnosis and the onset of an acute 
event that causes a patient’s admission to the ICU.  
The results provide evidence of the different behaviors of physiologic parameters during 
the recovery processes for survivors and non-survivors. These differences were observed during 
the first 8 to 10 days after a patient’s admission to the ICU. The application of the presented 
methodology could enhance physicians’ ability to diagnose more accurately, anticipate changes 
in recovery trajectories, and prescribe effective treatment, leading to more personalized care and 
reduced mortality rates.   
 1 
     
 
 
 
 
 
CHAPTER 1: INTRODUCTION 
 
1.1 Background 
One of the major concerns of the U.S. government is the situation of the healthcare 
system. There are several factors associated with this issue, and some have motivated the 
development of this research: (1) the current level of healthcare cost in the U.S., (2) the 
availability of massive datasets, (3) the lack of effective tools to help healthcare providers 
improve their diagnoses and the interpretation of results, and (4) high mortality rates. It is 
estimated that National Health Expenditures (NHE) currently are approximately 18 percent of 
GDP ($2.9 trillion), and they are expected to reach 19.9 percent by 2022 ($5.0 trillion) [1]. This 
concern is shared by both the private and public sectors, since U.S. government spending is 
approximately 20 percent of GDP [2]. The rapid advancements in healthcare information 
technology have led to massive and heterogeneous datasets. However, the amount of information 
that is currently extracted from those datasets is limited due to the complexity of health processes 
and the lack of tools to assist physicians in better analyzing and interpreting results. Physicians 
are usually not trained to simultaneously analyze multiple attributes and, often, their decisions 
are made based on the last test result as a last picture of the patient compared to “normal” ranges 
and their experience. The high mortality rates faced by U.S. hospitals are also an important issue. 
Cardiovascular diseases and post-surgical health management are two of the primary causes of 
death in U.S.: in general, 10–29 percent of patients admitted to adult intensive care units (ICUs) 
 2 
     
die in hospitals across the U.S. [3], and 23.7 percent of total deaths are caused by heart disease, 
which continues being the leading cause of death [4].  
The accurate assessment of the circulatory system is important for all critically-ill 
patients. Often, changes in circulatory status occur rapidly, with possible complications for the 
patient, and interventions and decisions have to be made as early as possible. Laboratory tests are 
the primary resource for diagnosing patient diseases and monitoring critically-ill patients. 
However, physicians often make decisions based on a single laboratory result, ignoring 
important factors such as patient historical test results and the relationships among different 
types of tests. They have a limited perspective of the role of commonly-measured parameters 
from the Complete Blood Count (CBC) test and the Basic Metabolic Panel (BMP) test and their 
interactions and changes over time. The CBC provides information regarding the types and 
number of cells in blood, and the BMP provides information about glucose, electrolytes, and 
fluid balance.  
There is a need to provide physicians with a dynamic patient profile and to develop 
methodologies and tools to assist (1) the extraction of pertinent knowledge from common and 
less expensive healthcare records (e.g., lab test results), (2) the anticipation of postsurgical 
adverse events, and (3) the provision of more personalized patient care. This study focused on 
modeling and analyzing multiple physiologic parameters, looking for a minimal set of markers 
that could assist physicians in timely identifying and assessing the risk of adverse events.  
The principal components of the blood are white blood cells, red blood cells, platelets and 
plasma, and platelets. The most common cells in the human body are red blood cells. They help 
the system in delivering oxygen (O2) to body tissues and carrying carbon dioxide (CO2) to the 
lungs to be exhaled. A reduced level of red blood cells, known as anemia, is the most common 
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disorder, which may lead to different clinical consequences. Plasma is a liquid that carries all the 
blood cells in suspension. It transports dissolved salts, proteins, nutrients, hormones, clotting 
factors, and electrolytes throughout the body as necessary. It also helps to remove waste products 
from the body. White blood cells help the body in fighting infectious diseases, attacking and 
destroying any bacteria or organism that causes the infection. Platelets are cells that bind and 
react to damaged blood vessels. They are related to the clotting of blood and prevention of 
bleeding. Therefore, platelets are relevant in heart attacks, strokes, and peripheral vascular 
diseases. A platelet count is the amount of platelets in the body. Too many or too few platelets 
may cause varied disorders. However, platelets can also present abnormalities in their function, 
which may lead to other disorders.   
There are also other physiologic parameters measured through blood tests that have been 
demonstrated to provide prognostic information. Two of them are albumin and calcium. Albumin 
is one of the main proteins of plasma. It is a component of acute injury response and decreases in 
response to inflammation. Therefore, it is also known as a negative acute phase reactant. It has 
been demonstrated to be a proper predictive marker of surgical complications, and low levels of 
albumin have been found in patients who have major sepsis (a very severe inflammation of the 
whole body, commonly caused by severe infection).  Additionally, several studies have 
suggested that albumin level can be an independent predictor of mortality in different clinical 
settings.   
Calcium is an important mineral in the human body. Blood calcium level is also a 
common test conducted as part of a basic metabolic panel test. Usually, it is measured when a 
patient presents symptoms suggesting kidney stones, bone disorders, or neurologic disorders. 
Blood calcium also has shown to be related to critically-ill patients, and some studies have 
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suggested that alterations in calcium levels occur frequently in the ICU patient population. The 
use of these and other parameters as markers are reviewed in Chapter 2 of this dissertation. 
 
1.2 Research Objectives 
This research aims to develop a generalizable methodology to assess dynamic changes of 
specific clinical parameters for a heterogeneous population of ICU patients, using rate of change 
and developing an index able to provide valuable information to anticipate adverse outcomes. 
The specific objectives of this research are to (1) develop a methodology to anticipate 
patient outcomes using dynamic changes in platelet count in a homogeneous population, (2) 
apply to a heterogeneous and complex dataset to determine the ability to generalize the results to 
a broader population, (3) extend the methodology to other parameters such as mean platelet 
volume, albumin, and calcium with the homogeneous dataset, and (4) generalize the 
methodology analyzing simultaneously specific parameters from a heterogeneous dataset. 
 
1.3 Organization 
This document is organized as follows: 
• Chapter 2 is a relevant literature review regarding common blood tests for patient 
monitoring, current practices associated with the analysis of laboratory test results, 
and monitoring techniques of patient recovery processes. Specific studies that use 
platelet count and calcium as markers are also presented, and the use of anion gap, 
total carbon dioxide, and albumin as parameters that can provide prognostic 
information is reviewed.  
 5 
     
• Chapter 3 presents the methodology applied, including a detailed description of the 
datasets and their construction, the study protocol, and details of the comparison of 
the two datasets selected. The statistics used to evaluate and validate the models are 
presented. These statistics allow the comparison of the models’ performance with the 
performance of other models from previous studies using similar physiologic 
parameters. 
• Chapter 4 presents the results for each step described in the methodology section and 
a discussion regarding the relevance of the results and their comparison with previous 
studies using physiologic data. 
• Chapter 5 includes conclusions, contributions, and the limitations of the research, as 
well as guidelines regarding further investigation to validate the results to be 
applicable for new ICU patients. 
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CHAPTER 2: LITERATURE REVIEW 
 
This chapter has four main objectives. First, it describes the basic hemodynamic 
parameters used to monitor patients during ICU patient recovery trajectories and their application 
in different studies as possible prediction markers of patient outcome. Second, it discusses the 
current practice associated with laboratory test analysis, as well as current practices in patient 
monitoring. Third, a detailed literature review in the use of platelet count as a predictor of patient 
outcome is discussed. The final section reviews the use of other physiologic parameters as part of 
patient monitoring.   
 
2.1 Common Blood Tests for Patient Monitoring 
Laboratory tests are a primary resource for diagnosing patient diseases and assessing 
patient progression. The most common tests ordered are the basic metabolic panel (BMP) and 
the complete blood count (CBC) test. The BMP is usually ordered as a routine medical exam.  
However, in critically-ill patients, the test can suggest medical causes of fluid imbalances that 
may require immediate intervention. The CBC is also a routine health laboratory test, but in 
critically-ill patients it provides information regarding disorders that affect blood cells. It is also 
performed to determine the effectiveness of treatments. Some therapies or medications can affect 
the production of cells, and a CBC is usually ordered to help monitor the treatments. 
  
 7 
     
2.1.1 Basic Metabolic Panel (BMP)  
A BMP is a group of blood tests that provide information about the patient’s metabolism. 
It is usually conducted to evaluate how the kidneys are functioning regarding blood fluid balance 
and blood sugar levels by measuring the levels of sodium, potassium, chloride, carbon dioxide, 
total bilirubin, total protein, glucose, creatinine, blood urea nitrogen (BUN), and calcium [5]. 
Blood sugar levels are measured in terms of glucose, one of the energy sources of the body. 
Fluid balance is measured in terms of electrolytes (potassium, calcium, and sodium). All 
contribute to the proper functioning of the nerves and muscles in the body. Creatinine and blood 
urea nitrogen are both waste products filtered by the kidneys. Their test results provide 
information on how well the kidneys are functioning. Abnormal results may be due to diverse 
conditions. These medical conditions may include kidney failure, diabetes, liver disease, 
breathing disorders, and side effects of medications [6]. 
2.1.2 Complete Blood Count (CBC) 
A CBC is commonly ordered to monitor disease progression with response to a treatment 
or as a routine checkup [7] for symptoms such as weakness, fatigue, or bruising [8].  A CBC 
provides information about the white blood cells, red blood cells and platelets. This test measures 
the number of white blood cells (WBC count), the number of red blood cells (RBC count), the 
fraction of the blood composed of red blood cells (hematocrit), and the total amount of 
hemoglobin in the blood. The test also provides information about the average red blood cell size 
(MCV), hemoglobin amount per red blood cell (MCH), the amount of hemoglobin relative to the 
size of the cell (hemoglobin concentration) per red blood cell (MCHC), and platelet count [8].  
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As described previously, all blood cells have different functions in the circulatory and 
immune systems (oxygen transport, blood clotting, infection and inflammation fighting) and, 
depending on their levels (low or high), diverse blood disorders with clinical consequences may 
appear. This test may provide physicians support in the diagnosis of allergies or diverse 
infections, detection of blood clotting problems or blood disorders such as leukemia or anemia,  
and the evaluation of red blood cell production or destruction [8].  
 
2.2 Current Practice in the Analysis of Laboratory Test Results 
The blood tests previously mentioned are the most common tests ordered to monitor 
patients and diagnose diseases. However, depending on the disease, physicians could order 
additional tests to confirm or discard any initial findings. This situation is more critical while 
assessing a patient’s progression in high-risk populations as ICU patients or patients suffering 
from chronic diseases. In these cases, more information is needed to make effective early 
decisions given the patient’s condition and the associated risks.  Care providers usually assess 
laboratory results by comparing them with “normal ranges,” which are based on specific healthy 
populations or on limits that characterize a specific medical condition. Moreover, these ranges 
depend on the methodology used to determine them; there is no standard methodology [9]. In 
addition, another issue is the difference across laboratories. Clinical laboratories use different 
techniques and methods to obtain results. Techniques, methods, and equipment are subject to 
various sources of variability, from calibration to materials to human skills. A study 
demonstrated that the severity of metabolic acidosis depends on the bicarbonate assay used.  The 
study concluded that the recognition of these differences is relevant for the definition of the 
severity of metabolic acidosis and the corresponding treatment [10]. 
 9 
     
Another important factor to consider is the variability among patients, even if they are 
part of a homogeneous population. The behavior of physiologic parameters varies among 
individuals; each person has her/his own “normal” ranges depending on personal conditions and 
characteristics. There is also variability within patients. This variability is affected by other 
factors in addition to the disease, such as emotional and environmental factors. For this reason, 
the analysis of test results should “ideally” be patient-specific. Unfortunately, the comparison of 
specific characteristics in a static “mode” of the patient’s condition does not provide physicians 
with the dynamism needed to understand the patient’s condition. The relationship among the 
results from the different tests cannot be effectively observed through static lenses. This research 
focuses on capturing the dynamism of specific physiologic signals through metrics that could 
provide useful information to the physician.   
 
2.3 Current Monitoring Techniques of Patient Recovery Process 
 There are several techniques applied to monitoring patient progress. Most of them 
monitor patients with cardiovascular diseases, because they continue being the leading cause of 
death in the U.S. [4]. The principal aspects considered during monitoring are the determination 
of the parameters that best represent the patient’s condition, the risks associated with the disease, 
and the modeling and prediction of patient outcomes [11, 12, 13]. The common parameters 
measured were described in the previous section; however, there is no agreement on which 
parameter—or set of parameters—can better describe a patient’s condition.  
 Many previous studies focused in using clustering methods to segregate the population, 
looking for similarities among patient characteristics. Some clustering methods have been 
modified to be applicable to dynamic environments (e.g., k-means or agglomerative hierarchical 
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method) for specific purposes such as fuzzy logic-clustering. One study applied a fuzzy logic 
clustering method for functional magnetic resonance imaging (fMRI) for the detection of brain 
activation during the application of a stimulus [14]. However, laboratory sampling procedures 
are not standard and samples are not taken at specific intervals. Thus, time series analysis has 
been used to analyze data dynamically, and clustering time series data have been used in various 
application domains [15]. Taking into account the development of healthcare information 
technology and the increment of healthcare data registered, the interest in temporal data mining 
research has increased. The principal difference between a static and a dynamic time series is the 
methodology used to measure the similarities between two patients or data objects.  
Time series has been also applied in detecting influenza epidemics [16] and modeling 
influenza incidence [17]. Nevertheless, to apply times series, the sample size takes an important 
role and, depending on the time frame, sometimes the values assigned to the parameter of 
interest, which are averaged values, are not representative of the real values associated with the 
time series. This issue is more important in the case of physiologic parameters, because their 
changes or variability over time are high due to different factors, and the samples are taken by 
request of the physicians and not on a regular basis. For example, in the case of platelet counts, 
factors such as invasive procedures, transfusions, catheters, or platelet function defects or blood 
or bone marrow disorders may affect the level of platelets.   
 Other studies have focused on the use of Markov processes [18, 19] to model disease 
progression, such as infectious diseases. Peng et al. [20] applied sequential cluster methods to 
establish the classification of the infectious disease state and then presented a weighted Markov 
chain procedure to predict the future incidence state. However, few studies have modeled the 
temporal evolution of postsurgical recovery and have used laboratory test results as a primary 
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source.  One study used multivariate time series, applying fuzzy logic methodologies to cluster 
patients after cardiac surgery. The multivariate clustering allowed the representation of potential 
risks associated with patients during their recovery process and clustering them into groups to 
further generate risk profiles per group [21].  
 
2.4 Platelet Count as a Biomarker 
A platelet count measures the amount of platelets in the blood. Platelets are blood cell 
fragments that travel in blood vessels and clot and are the smallest type of blood cell. One of the 
most important functions is the formation of blood clots. If a blood vessel is damaged, then the 
platelets clump and form a plug (called platelet aggregation) that will help stop bleeding. 
Platelets also contribute in inflammatory processes in tissue. They are also called thrombocytes, 
because a blood clot also is called a thrombus [22].  The number of platelets can be altered by 
diverse diseases and conditions (such as bone marrow or immunologic problems, liver disease, 
or some medications), and they may be counted to monitor or diagnose diseases. According to 
the National Institute of Health, the reference range for a platelet count is from 150,000 to 
450,000 units per microliter (mcL) [23]. 
Abnormalities in platelet numbers and functions are coagulation disorders observed in 
ICU patients [24]. An abnormal drop in the number of platelets in the bloodstream, known as 
thrombocytopenia, may result in increased bleeding. Thrombocytopenia may be result of a 
deficit in platelet production, an excess in platelet destruction, or an increment of consumption in 
the bloodstream. Some studies have found associations between a decline in platelet counts and 
patient outcomes [25], whereas a decline in platelet counts for patients who stayed more than 
five days in an ICU provided prognostic information. Some studies have focused on platelets 
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recognizing that they are involved in the pathogenesis of sepsis and that the severity of sepsis 
correlates with the decrease in platelet counts [26]. Other studies have reported that ICU 
mortality is significantly higher in thrombocytopenic patients [27, 28, 29, 30].  
Baughman et al. [27] reviewed 162 records of ICU patients and concluded that 
thrombocytopenia was common in ICU patients and was associated with longer hospital stays 
and increased mortality. This was an issue supported by Greinacher et al. [30], who reported that 
approximately 40 percent of the ICU patients had thrombocytopenia. Stephen et al. [28] 
conducted a study with 147 ICU patients with surgical intervention. The data was collected 
during six months and the conclusion was that thrombocytopenic patients had a higher mortality 
and that this condition probably was a reflection of the magnitude of an underlying pathologic 
condition. The authors also suggested that the correction of this condition may be an appropriate  
prognostic factor. Thrombocytopenia was defined as a risk factor for mortality in a study that 
analyzed thrombocytopenia during sepsis. The authors evaluated if this condition could predict 
mortality in ICU patients [29]. This study also reported that the platelet count in survivors was 
higher than in non-survivors. 
It can be observed in all these studies that low levels of platelet count are very risky and 
may suggest the severity of an illness; however, an elevated number of platelets, known as 
thrombocytosis, could cause spontaneous blood clots, which may be risky as well. 
Thrombocytosis may be present due to an infection or any blood or bone marrow disorder, but, 
in those cases, platelets may take part in the coagulation of arteries with the possibility of 
causing atherosclerosis. These types of disorders also are important, because they can cause vein 
thrombosis, or any thrombosis that may lead to stroke or heart attack.  
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As mentioned, platelet disorders also could be related to their function.  Platelet adhesion 
(to the vessel walls), aggregation, and activation may be affected in critically-ill patients. 
However, tests associated with measuring the ability of adhesion or aggregation are influenced 
by several factors and are not common.  These parameters were not available in the datasets 
analyzed, nevertheless, it is important to note that these abnormalities exist and may affect 
patient clinical outcomes.  
Finally, another characteristic of platelets is platelet volume, which can be estimated as 
part of a CBC test. Some studies have suggested that an increment in MPV may increase 
mortality risk in ischemic heart diseases [31].     
Although it has already been recognized that “determining trends in platelet count is of 
additional prognostic value compared with single measurements” [32], none of the studies have 
looked in more detail at the dynamic changes in platelets, nor have they identified any specific 
signal or marker that can alert physicians for possible complications.     
Considering the importance of platelets in monitoring ICU patients, it seems appropriate 
to study their behavior over time and develop a methodology to capture their change as a 
predictor of patient outcome.  Since this behavior is critical for patients with heart disease, this 
research has two parts: (1) investigate a specific group of ICU patients with heart disease who 
underwent specific types of cardiac operations and (2) investigate a mixed population of ICU 
patients from different hospitals and with varied conditions. The objective is to develop a 
methodology to predict patient outcomes with a homogeneous cardiac dataset and then replicate 
or redefine the methodology for a heterogeneous and more complex dataset.  
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Nijsten et al. [33] conducted a retrospective study to analyze the relevance of time-
dependent changes of platelet counts in ICU patients. The study found an association between 
patients with low rate of change in platelet count and  mortality. The authors observed that 
between days 2 and 10, non-survivors had a smaller increase in platelet counts than survivors. 
The rate of change was calculated daily and the result was comparable with the Acute 
Physiology Chronic Health Evaluation II (APACHE II; [33]) score in predicting mortality, which 
uses the leukocyte (white blood cell) count.   
Another study conducted by Akca et al. [35] focused on describing the changes of 
platelet count over time and relating them to mortality rate in critically-ill patients. This 
prospective study included data from 40 ICUs gathered in 16 countries. The patient population 
enrolled in the study included 1,449 critically-ill patients, but only 257 stayed for more than 2 
weeks in the ICU. The study showed a biphasic pattern of platelet count, which was different in 
survivors and non-survivors, and concluded that late thrombocytopenia (platelet count less than 
150x103/mm3) was a better predictor of death than early thrombocytopenia. The authors also 
observed that after thrombocytopenia, the platelets increase for survivors, issue that was not 
observed in non-survivors. They concluded that the platelet count decreased significantly in the 
first three days after admission, reaching a low point on day 4 for both survivors and non-
survivors.  
After review of these studies, it can be concluded that the analysis of changes in platelet 
count over time is important in critically-ill patients and may provide prognostic information. In 
all of the reviewed studies, thrombocytopenia was presented in critically-ill patients, suggesting 
that low platelet count is related to patient outcome and mortality.  
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The next section describes other hemodynamic parameters that have shown to be related 
to clinical outcomes and may also provide additional information regarding patient progression. 
Therefore, they may be considered for inclusion in our predictive models.  
 
2.5 Other Parameters used to Monitor Patient Progression 
Several commonly-measured parameters help physicians monitor patients. Depending on 
the disease and the patient’s condition, the tests vary, but the primary source is blood tests. As 
explained, the blood has basic components, but there are other physiologic attributes measured in 
the blood, such as albumin and calcium, that have been demonstrated to provide prognostic 
information. Albumin is an important protein of blood plasma; it regulates the colloidal osmotic 
pressure of blood and transports hormones and fatty acids, among others. Some studies that have 
found that reduced levels of albumin concentration are associated with mortality risk [36].  Other 
studies have found that a low level of albumin (hypoalbuminemia) in patients with critical 
conditions is associated with poor outcomes [37, 38], and others that low albumin concentration 
in the blood independently predicts morbidity [39]. The impact of albumin levels in critically-ill 
patients has been observed and analyzed by several researchers. Most studies have observed that 
albumin levels decrease at the beginning of a critical illness and continue without increasing until 
the recovery phase [39]. 
Calcium is the most common mineral in the human body and one of the most important.  
Most calcium is found in bones, but a small amount is found in blood. Calcium affects bone and 
teeth building, but it also influences the nervous system and the blood clotting process. When 
blood calcium levels are low (hypocalcemia), calcium is extracted from the bones; when the 
calcium level in the blood is high (hypercalcemia), the body stores it in the bones or discards it. 
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Blood calcium also has shown to be related to critically-ill patients. Some studies have suggested 
that alterations in calcium levels occur frequently in the ICU patient population. Hypocalcemia 
has been reported in critically-ill patients, and decreased calcium levels have been correlated 
with increased mortality [40]. Another study found a drop phase in plasma calcium for patients 
who underwent cardiac surgery [41]. In this study, all patients were survivors, but all had a 
significant drop in plasma calcium, reaching a minimum during the second day after surgery. 
However, patients with other complications reached minimum values six days after surgery.   
Two other parameters that could be explored as possible markers are the anion gap and 
total carbon dioxide (TCO2).  The anion gap in blood is the difference between cations 
(positively-charged ions) and anions (negatively-charged ions) in serum. It is a common measure 
used to identify the cause of metabolic acidosis, that is, a lower-than-normal pH in the blood.  
However, it has been used not only to diagnose acid-base disorders but also to diagnose other 
conditions. One study concluded that an increased anion gap at admission is a predictor of 
patient mortality in the critically-ill [42]. Another study investigated increased anion gaps and 
their clinical significance and concluded that the increment in anion gap is related to an increased 
severity of illness that is independent of severe electrolyte abnormalities [43]. In this study, 
hospitalized patients who survived at least one week showed low risk of mortality. 
The TCO2 test often is conducted as part of the BMP. The process of metabolism 
produces carbon dioxide in our blood. Both high and low levels of TCO2 in the blood may 
impact different systems related to cardiovascular functioning or cellular-based respiration. 
These changes may suggest the retention or loss of fluids, which may cause an imbalance in the 
body’s electrolytes [44]. If a patient presents low levels of carbon dioxide, then less oxygen will 
reach the cells and tissues. On the other hand, if a patient presents high levels of carbon dioxide, 
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it may suggest a lung disease or infection. TCO2 is correlated with the anion gap and is 
commonly measure for the diagnosis of metabolic acidosis, when the value falls below the lower 
“normal” limit of 23 mEq/L. Additionally, “metabolic acidosis has been recognized as an 
important comorbid event in the high mortality rates seen in patients with end-stage renal 
disease” [10].  
To summarize, this chapter reviewed different parameters that have been used as 
biomarkers and that have been demonstrated, through several studies, to provide prognostic 
information. Also reviewed were different techniques or practices used for patient monitoring. 
Some of the most relevant studies reviewed were related to platelet count and its impact in 
patient monitoring processes and its correlation to patient outcome, including morbidity and 
mortality.  
It is important to note that the level of platelets in blood depends on several processes 
(platelet production, maturation, sequestration, and destruction). All of these processes are 
affected by different factors, from the individual patient’s characteristics and condition to drugs 
and treatments. Identifying changes in platelet count over time may provide new information 
about the underlying “systems” and a new understanding of the disease processes themselves. 
Similarly, modeling changes in some component elements of the BMP will support identifying 
changes in underlying “systems” that are elements of basic disease responses. In the following 
chapter, the methodology developed to analyze the parameters previously mentioned and 
reviewed in this chapter are described.   
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CHAPTER 3: METHODOLOGY 
 
This chapter presents the methodology developed to achieve the goals of this study. First, 
the two different patient populations selected are described, and the reference event is defined for 
each dataset.  Second, the study protocol is presented, which describes the metrics developed and 
presents the independent analysis of platelet count changes in each dataset. A key factor in the 
methodology is the process of synchronizing patient care cycles so that the changes of the 
parameters over time can be captured and compared. Third, a comparison of the results from 
both datasets is presented. Finally, the statistics applied to assess the metrics and the 
classification models and to compare the datasets are described. Considering specific objectives 
(1) and (2) the sequence to achieve them is the following: (i) selection of patient population, 
including determination of primary events, (ii) analysis of VA dataset, including definition of 
time frame (specific times intervals) and analysis of both metrics—rate of change and ratios in 
previously-defined time intervals, (iii) repetition of methodology applied to platelet count with 
MIMIC II dataset and (iv) graphical and statistical comparison of both datasets.  
Objectives (3) and (4) of this research are related to broadening the scope to other 
parameters. To achieve them, the following activities will need to be conducted: (i) application 
and verification of methodology to other physiologic parameters using the homogeneous dataset, 
including individual analysis of each parameter, (ii) validation of methodology to simultaneously 
analyze homogeneous population and (iii) individual and simultaneous analysis of additional 
parameters from MIMIC II dataset.  
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Figure 3.1 presents a diagram of the methodology description, including the specific 
research objectives and the sequence of activities to achieve them. 
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Figure 3.1. Methodology description 
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3.1 Patient Population’s Selection 
Two databases were used. The first database was composed of patients undergoing 
cardiac surgery at the James A. Haley Veterans Hospital (VA) in Tampa, Florida. The main 
focus was to analyze the behavior of changes in platelet counts over time using a more 
homogenous population. The second database was the MIMIC II clinical database (version 3), 
which is a component of the PhysioBank Archives, developed at the Massachusetts Institute of 
Technology (MIT) and at Boston’s Beth Israel Hospital [44]. A heterogeneous sample of ICU 
patients was selected with different conditions and several hospital admissions. The purpose of 
using this database was to determine if the methodology could be generalized to a more 
heterogeneous population.  
The first database contained 406 patients who underwent cardiovascular surgery 
(coronary artery bypass, aortic valve replacement, and mitral valve replacement) at the VA for a 
period of 3 years. The date and time of surgery were selected as the reference time. All platelet 
count values were assigned a relative time (in hours) from the reference time. 
The second database contained records of more than 30,000 patients from a period of 7 
years. All patients with platelet count values recorded were selected. The sample contained 1,308 
de-identified ICU patients. More than a single admission was considered for survivors, but only 
last admissions were considered for non-survivors. As a result, 1,999 cases (a combination of 
patients and hospital admissions) were included for analysis. The original dataset included 15 
percent of the population whose specific ICU admission time and date were unknown, 56 percent 
whose platelet count tests were taken after ICU admission, and 29 percent whose tests were 
taken before ICU admission. Considering the heterogeneity of the sample and that the exact ICU 
admission time was not available for all patients, the minimum platelet count value during the 
 21 
     
first 24 hours after the first registered measure was selected as reference event or starting point 
for further analysis. The initial analysis of the more homogeneous cardiac surgery dataset 
suggested that platelet counts fall promptly after an acute event, which formed the basis for 
selecting this time interval to “synchronize” the patients’ care cycles.  The relative time to this 
event was computed for each subsequent platelet count value. 
 
3.2 Study Protocol 
3.2.1 Analysis Using the Veterans Hospital Dataset  
3.2.1.1 Definition of Time Intervals 
The behavior of survivors and non-survivors was analyzed by defining two specific 
reference points: At  as the average time corresponding to the minimum platelet count for 
survivors, and Bt  as the average time corresponding to the minimum platelet count for non-
survivors. An analysis period was defined based on the platelet count behavior for survivors and 
non-survivors.  A maximum period of 3t  hours was selected based on the platelet count changes 
observed and on the literature review that supports a minimum time that could provide 
prognostic information. Time intervals relevant to the study were defined as  11 , ttT A , 
 22 , ttT A  and  33 ,ttT A , where At  is used as the starting point of analysis, and 1t , 2t , and 3t
were defined as the upper limits of the time intervals. Intervals longer than 3t  hours were 
considered to be too late in the care cycle to be prognostically useful. Three other intervals were 
defined:  14 , ttT B ,  25 , ttT B , and  36 , ttT B , using Bt  as the starting point.  
3.2.1.2 VA Dataset Analysis with Rates of Change and Ratios  
iRc was defined as the rate of change of platelet counts over intervals iT , 3,2,1i . Mean 
rates of change for survivors and non-survivors over those intervals were computed. These ratios 
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were subsequently compared to a more comprehensive analysis of the slope, anticipating that the 
simpler calculation of the ratio of values at two time points would be more usable in a clinical 
environment.  A similar procedure was conducted for 54,TT , and 6T . Using those intervals, rates 
of change per hour jRc , 6,5,4j  were computed, and mean rates of change for survivors and 
non-survivors were calculated. Looking for a simple metric to analyze the platelets, three 
specific ratios were tested. We defined 
A
i
i PLT
PLTr  , 3,2,1i  where iPLT  represents the platelet 
value measured at time it  and APLT  represents the platelet value measured at At . 
Since measures were taken at different time intervals, a 10-hour interval was used to 
search values at the points it  previously defined—i.e., the nearest measure to it  was searched 
inside the interval  ii tt ,10 , 3,2,1i . Ratios ir  were computed for all patients and mean ratios 
were calculated.  
A similar procedure was conducted using Bt  as the starting point. Using the intervals
6,54 ,, TTT , jr  was computed as 
B
j
j PLT
PLT
r 3 ,, 6,5,4j  where BPLT  represents the platelet value 
measured at Bt . 
3.2.2 Analysis Using the MIMIC II Dataset  
The primary event or starting point for each patient was defined as the time 0t  for the 
minimum platelet value during the first 24 hours after the first measure registered. All platelet 
values registered after 0t  were considered, and all corresponding time values were calculated 
with respect to time .0t  The methodology applied for the first dataset was repeated with the 
second dataset using the previously-defined relative times and platelet values. 
  
 23 
     
3.2.2.1 MIMIC II Dataset Analysis with Rates of Change and Ratios  
To construct the intervals iT , 6,...,1i , times At , Bt , 1t , 2t and 3t  were defined as relative 
times with respect to 0t . Using the platelet values recorded during the intervals iT , 6,...,1i , 
rates of change per hour ( Rc ) were computed over each interval. Then, mean rates of change for 
survivors and non-survivors over the defined intervals were computed. The same procedure was 
followed using the second dataset; mean ratios were calculated using the same time intervals 
differentiating survivors and non-survivors.  
 
3.3 Analysis and Comparison of the Datasets 
Both datasets were analyzed individually to assess if the defined metrics could 
differentiate survivors from non-survivors. Then, both datasets were compared. The analysis was 
conducted graphically and statistically, comparing rates of change and ratios over each time 
interval. The objective was to analyze if the results from both datasets were comparable and if 
the methodology could be extended to a heterogeneous dataset. A critical assumption was that 
the values selected as first value and minimum value of the ICU patients from the MIMIC II 
dataset were realistic surrogates for the time of an actual acute event, because all the relative 
times computed were measured considering the time of this first registry as reference or time 0.  
 
3.4 Multivariate Analysis  
3.4.1 VA Multivariate Analysis 
 To evaluate if the methodology could be applied to other parameters, other physiologic 
parameters from the VA population were analyzed.  The parameters available from this dataset 
were calcium, albumin, ionized calcium, and mean platelet volume (MPV). Calcium as a 
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biomarker and predictor of patient outcome was reviewed in the previous chapter. Ionized 
calcium (also called free calcium) is the calcium not attached to any protein in blood and helps in 
the building of bones and teeth. The behavior of this parameter was previously analyzed as a 
biomarker of patient outcome in cardiac surgery patients [40]. Mean platelet volume is another 
characteristic of platelets and may provide information on the speed of platelet production and 
release in the blood stream. It may be combined with platelet count to obtain a surrogate of 
platelet mass.  Mean platelet volume is a surrogate for platelet age and, combined with platelet 
count, allows the estimation of the platelet mass, as shown in equation (1). 
MPVPLTPLTmass                                    (1) 
 With these platelet mass estimates, both metrics (ratios and rates of change) were 
calculated and assessed.  Finally, the ratios and rates of change from all the parameters measured 
in the dataset were independently calculated and analyzed, and several parameters were analyzed 
simultaneously. To better observe the relationship between parameters, contour plots and surface 
plots were presented. The results of all the models created were compared with the results 
achieved with the platelet count values for the same group of patients. 
3.4.2 MIMIC II Multivariate Analysis  
The same methodology was applied with other parameters from the MIMIC II dataset. 
The parameters under study were albumin, calcium, anion gap, and total carbon dioxide. The 
characteristics of those parameters and their impacts on patient outcomes, including mortality 
and morbidity, were reviewed in the previous chapter. Of note is that unlike the VA dataset, 
where the parameter values were taken at the same time and from a specific group of cardiac 
patients (406 cardiac surgery patients), in the MIMIC II dataset, the different parameters to be 
analyzed were taken at different times and may come from a different set of patients from the 
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population (30,000 patients with diverse diseases). In this study, all cases registered for each 
parameter were considered, independent of the patient. Finally, several models were assessed to 
evaluate if their prediction power could be improved. In those models, the samples were per 
admission and not per patient.  
 
3.5 Statistics  
Fundamental basic descriptive statistics (mean and standard deviation) were used to 
evaluate the results. Two sample t-tests were conducted to evaluate differences in mean rates of 
change and mean ratios between survivors and non-survivors and also to evaluate differences 
between both datasets. Precision was given by one standard deviation (SD), and 95% confidence 
intervals (CI) were calculated for the means and medians. Medians were used in the cases of 
non-symmetric distributions.  
Binary logistic regression models were developed using both metrics. The analysis of 
maximum likelihood estimates and likelihood ratios (LR) to evaluate the models were conducted 
using 2 test. Odds ratios (ORs) and corresponding 95% Wald confidence intervals for the 
selected factors were calculated and used for the analysis. The odds ratio was calculated by 
dividing the probability of non-surviving by the probability of surviving. The c-statistic was used 
to evaluate the performance of the logistic regression models and to compare the study results 
with previous studies. This statistic represents the area under the receiver operating characteristic 
(ROC) curve and was used to assess the discriminative power of the metrics.  
Additionally, sensitivity analysis using bootstrapping was conducted to analyze the 
uncertainty of the parameter estimates, and 95% CI for those estimates were calculated. Ten-fold 
cross validation was used for the classification models; analysis of variance (ANOVA) was used 
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to evaluate the selected regression model; mean square error (MSE) and the predicted residual 
sum of squares statistic (CV press) were used to assess the models with both metrics over 
different intervals and compare them. Statistical significance was accepted at p-value ≤ 0.05. 
Data were managed using scripts in Matlab R2012a and analyzed using Minitab 16 and SAS 9.3.  
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CHAPTER 4: RESULTS AND DISCUSSION 
 
This chapter presents the results and a discussion comparing these results with the results 
of previous studies. First, the behavior of platelet counts with the population from the VA dataset 
was reviewed, and then the behavior of the same parameter from the heterogeneous population 
was analyzed. The means for the defined metrics were compared graphically and statistically, 
including rates of change and ratios for specific time intervals in both datasets. Second, other 
parameters from the VA dataset were analyzed simultaneously. Third; other parameters from the 
MIMIC II dataset were also analyzed, individually and simultaneously. The last part of the 
chapter presents a discussion of the results and their impact in the patient monitoring process. 
 
4.1 Results 
The results shown below follow the sequence mentioned in the methodology section. In 
that section, two populations were described: a dataset from the VA and the MIMIC II dataset. In 
both datasets, the specific reference or acute events were defined. All the time values 
corresponding to each parameter value were relative times measured with respect to the time of 
the defined reference event. First, the results from the VA dataset were reviewed by applying the 
methodology to all the defined time intervals and then, the results from the MIMIC II dataset 
were reviewed. Then, both datasets were compared graphically and statistically. The next step 
was to repeat the methodology with other parameters from the VA dataset. Finally, other 
parameters from the MIMIC III dataset were reviewed by applying the methodology to specific 
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time intervals. Some observations from the graphs and comments are included after each result, 
and the final comments and conclusions are presented in Section 4.2. 
4.1.1 VA Dataset 
A total of 406 patients were analyzed from the VA dataset, which included 365 survivors 
and 41 non-survivors. Figure 4.1 shows the behavior over time of the platelet count for a sample 
of 56 patients, (survivors and non-survivors) during the first 300 hours after surgery. As can be 
seen, a drop occurred during the first 100 hours after surgery and then a rise of the platelets 
occurred, a fact that is more notable in survivors than non-survivors. During the interval of 300 
hours, platelets for survivors continued to rise, while for non-survivors they did not. 
Nevertheless, in both cases, minimum values were observed during the first 100 hours.  
 
 
Figure 4.1. Platelet count over time - VA dataset 
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The time for the minimum platelet value after surgery for each patient was registered. 
The mean time for that minimum value was 53.4 28.31 hours (95% CI = [51.9,54.8] ) and 
77.05  59.69 hours (95% CI = [67.7,86.4]) for survivors and non-survivors, respectively. 
Observing the high variability, 95% CI for the median were calculated. The confidence intervals 
computed were [52,52] hours and [52,76] hours for survivors and non-survivors, respectively. 
Considering mean and median values from the previous results, At  (average time corresponding 
to minimum platelet count for survivors) and Bt  (average time corresponding to minimum 
platelet count for non-survivors) were set to 50 and 75, respectively. These times allowed the 
definition of the lower limits for the time intervals to be analyzed with the proposed metrics of 
rates of change and ratios.  
It is important to note that the mean minimum platelet value for this population was 125.2
 47.58 x109/L for survivors and 139.9 85.63 x109/L for non-survivors. However, median 
values were more representative, with 95% CI of [120.31,130.31] x109/L for survivors and 
[84.28,174.72] x109/L for non-survivors. Through both confidence intervals from the mean and 
the median, the variability in non-survivors was almost two times the variability presented in 
survivors for the minimum platelet value. However, in all cases, minimum platelet values were, 
on average, less than 150 x 109 /L, the “normal” reference range [23]. This issue confirms the 
statement that thrombocytopenia is commonly present in critically-ill patients such as this group 
of cardiac patients.  
Observing the general behavior of platelet count (see Figure 4.1), a drop below 
150x109/L occurred for the majority of the patients, and then the platelet count normalized or 
rose above this value during the first 200 hours. This fact agrees with the findings of prior 
authors, who found a clear decrease in platelet count during the first days in ICU [33, 46, 47]. A 
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similar situation was observed by Akca et al. [35], where platelet counts decreased in the first 
three days to reach a low point on day 4 for both survivors and non-survivors. It was established, 
then, that 2003 t  hours, and the study focused on intervals within this time frame. 
Time intervals were defined as  100,501 T ,  150,502 T  and  200,503 T  for the first set 
and  100,754 T ,  150,755 T and  200,756 T  for the second set. Using these time intervals, the 
behavior of the rates of change and the behavior of the ratios were analyzed. Table 4.1 shows the 
basic descriptive statistics for the mean rates of change in survivors and in non-survivors. As 
shown, there was an increment in the mean rate of change for all intervals from 1T to 6T in both 
survivors and non-survivors. Nevertheless, if only one of the intervals is observed, there is also a 
clear difference between mean rates of change in survivors and non-survivors, with the mean rate 
of change for survivors being more than two times the rate of change of non-survivors. Another 
result is that the variability increased when the intervals 6,54 ,, TTT  were used, which means that 
the rate of change varied more when analyzing intervals beginning 75 hours after surgery.  
 
Table 4.1. VA rates of change iRc , jRc - Descriptive statistics. S, survivors and NS, non-
survivors 
iRc   1Rc   2Rc   3Rc  
  S NS  S NS  S NS 
Sample size  339 33  343 34  343 36 
Mean (x109/L/h)  0.672 0.238  1.035 0.430  1.153 0.541 
Standard Deviation  0.695 0.830  0.662 0.664  0.662 0.599 
jRc   4Rc   5Rc   6Rc  
  S NS  S NS  S NS 
Sample size  293 28  323 30  326 32 
Mean (x109/L/h)  1.211 0.358  1.452 0.579  1.516 0.654 
Standard Deviation  1.066 0.933  1.564 0.716  1.533 0.653 
 
Figure 4.2 shows the typical behavior of platelet counts along interval 3T (between 
approximately day 2 and day 8 after surgery). A difference in slopes between survivors and non-
survivors can be observed. In this example, survivors presented a higher rise in platelet counts 
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than non-survivors. Moreover, most of the non-survivors maintained platelet count values of less 
than 100x109/L, which categorized them as thrombocytopenic patients [35], confirming the 
results from previous studies that found associations between thrombocytopenia and mortality 
[27,29].  In this figure, it also can be observed that the platelet count decreased for a couple of 
patients; however, although the platelet value stabilized around 200x109/L, which is considered a 
normal value, the patients did not survive. This may be an example of situations where a disorder 
in the platelet function is present or an adverse event occurred due to an unexpected factor. As 
defined previously, ratios ir  and jr were used to estimate the slope with two points, the interval 
limits. To find the platelet values at 50, 100, 150, and 200 hours, the following intervals were 
defined: [40,50], [90,100], [140,150] and [190,200], respectively. The nearest value to the upper 
interval limit was used to determine the platelet value for calculating the corresponding ratio. 
 
 
Figure 4.2. Platelet count over time in 3T -VA dataset  
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 Table 4.2 shows that the mean ratios and its variability increased according to the time 
interval length. All mean ratios calculated for survivors were greater than the mean ratios for 
non-survivors, confirming that the platelet counts rose more quickly in the former than in the 
latter.  
 
Table 4.2. VA ratios ir , jr - Descriptive statistics. S, survivors and NS, non-survivors 
ir   1r   2r   3r  
  S NS  S NS  S NS 
Sample size  254 28  169 21  112 19 
Mean  1.280 1.098  1.809 1.324  2.395 1.573 
Standard Deviation  0.285 0.252  0.545 0.452  0.960 0.754 
jr   4r   5r   6r  
  S NS  S NS  S NS 
Sample size  271 27  185 22  119 19 
Mean  1.221 1.099  1.787 1.324  2.398 1.571 
Standard Deviation  0.203 0.194  0.591 0.324  1.110 0.819 
 
To assess the results shown and evaluate if both metrics (rates of change and ratios) can 
differentiate survivors from non-survivors, two sample t-tests for the differences in mean were 
conducted. Of note is that the sample sizes for rates of change (321  N  379) were larger than 
the sample sizes for ratios (131 N  298). However, the proportion in percentage of non-
survivors with respect to survivors was larger in ratios (between 10 and 17%) than in rates of 
change (between 9 and 10%). The tests showed that the mean rates of change from survivors and 
non-survivors were statistically different (p-value = 0.0060 for 1T  and p-values < 0.00001 for all 
other intervals). The same result was obtained for the mean ratios (p-value = 0.001 for 1T  and p-
values < 0.00001 for all other intervals).  
4.1.2 MIMIC II Dataset 
This dataset was composed of 1,308 ICU patients with 1,999 admission cases and 23,665 
platelet count measures. The time for the minimum platelet value after the reference time was 
registered. The mean time was 96  146 hours for survivors and 144.7 199.8 hours for non-
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survivors.  The median values were more representative, with 95% CI of [48.0, 51.3] and [60.3, 
84.9] hours for survivors and non-survivors, respectively. As can be observed, the reference 
times set at 50At and 75Bt  could be also used for this dataset, so that a comparison between 
both could be conducted.  
Figure 4.3 shows the behavior of the platelet count for 30 cases, where the rate of change 
from survivors is higher than the rate of change from non-survivors. The difference in platelet 
count between survivors and non-survivors were not as notorious as the difference showed by the 
VA population from Section 4.1.1. However, it can be observed that platelet values for survivors 
reach normal values (150x109/L) between 200 and 300 hours, while for non-survivors the 
platelets maintain values less than the normal values.  
 
 
Figure 4.3. Platelet count over time - MIMIC II dataset  
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The mean minimum platelet value was 178.2  98.5x109/L for survivors and 137.4
94.8x109/L for non-survivors. Nevertheless, median values were more representative, with 95% 
CI of [157.0, 166.0] for survivors and [105.1, 133.8] x109/L for non-survivors, respectively.  
Table 4.3 shows an increment in the mean rate of change for all intervals 1T to 6T for 
survivors and non-survivors. However, observing each one of them, there was also a difference 
between mean rates of change from survivors and non-survivors. As observed in the VA dataset, 
the variability increases for intervals 4T , 5T and 6T . The greatest difference in the mean rate of 
change was shown for 3T (0.50x10
9/L/h), and in 2T  the mean rate of change of survivors was 18.2 
times the mean rate for non-survivors. 
 
Table 4.3. MIMIC II rates of change iRc , jRc - Descriptive statistics. S, survivors and NS, non-
survivors 
iRc   1Rc   2Rc   3Rc  
  S NS  S NS  S NS 
Sample size  1012 235  1100 240  1122 240 
Mean (x109/L/h)  0.284 -0.024  0.473 -0.020  0.565 0.062 
Standard Deviation  2.519 2.98  1.170 1.470  1.084 1.400 
jRc   4Rc   5Rc   6Rc  
  S NS  S NS  S NS 
Sample size  268 75  935 218  974 222 
Mean (x109/L/h)  0.078 -0.14  0.507 0.070  0.575 0.133 
Standard Deviation  5.107 4.934  2.405 1.800  2.290 1.680 
 
Using the same ratios defined for the VA dataset for all intervals 1T to 6T , the results for 
ir  and jr are shown in Table 4.4. As shown in Table 4.3 for the rates of change, the mean ratios 
increased according to the time interval length, and the mean ratios for survivors were greater 
than the mean ratios for non-survivors in almost all cases. Only in the case of the interval 4T  the 
mean ratio for survivors was less than the mean ratio for non-survivors. 
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Table 4.4. MIMIC II ratios ir , jr - Descriptive statistics. S, survivors and NS, non-survivors 
ir   1r   2r   3r  
  S NS  S NS  S NS 
Sample size  468 117  336 90  238 68 
Mean  1.074 0.975  1.291 1.048  1.522 1.186 
Standard Deviation  0.282 0.594  0.557 0.455  0.948 0.675 
jr   4r   5r   6r  
  S NS  S NS  S NS 
Sample size  486 122  344 96  244 75 
Mean  1.059 1.094  1.271 1.146  1.468 1.261 
Standard Deviation  0.194 0.698  0.442 0.595  0.810 0.730 
 
Table 4.4 shows that, unlike the sample sizes found for survivors and non-survivors 
derived by the computation of the metrics with the VA population, the sample sizes for rates of 
change (363 N  1362) were larger than the sample sizes for ratios (306 N  608), but not in 
all cases, and the proportion in percentage of non-survivors with respect to survivors were 
similar, between 25 and 30 percent for ratios and between 21 and 27 percent for rates of change.  
Two sample t-test showed that almost all mean rates of change from survivors and non-survivors 
were statistically different (p-value = 0.738 for 1T  and p-values < 0.003 for all other intervals). A 
similar result was obtained for the mean ratios (p-value = 0.595 for 4T , p-value = 0.057 for 5T  
and p-values < 0.038 for all other intervals).  
4.1.3 Comparison of the Datasets 
To visualize the difference of both datasets in terms of the rate of change, cases 1, 2 and 3 
were defined for the mean rate of change calculated for the intervals  1T , 2T and 3T , respectively 
(See Table 4.1 and Table 4.3). Figures 4.4(a) and 4.4(b) show the mean rate of change for 
survivors and non-survivors, respectively. The dashed lines represent the trend of the VA dataset 
and the solid lines represent the trend of the MIMIC II dataset. In both figures, the trend is very 
similar. In both datasets, the mean rates of change increased as the interval length increased.  
  
 36 
     
In general, it can be observed that the VA population had higher mean rates of change 
than the population from the MIMIC II dataset. The differences in mean rate of change were 
between 0.44 and 0.58 x109/L/h for survivors and between 0.45 and 0.53 x109/L/h for non-
survivors. In both cases—survivors and non-survivors—the differences were very similar, an 
issue that can be observed in Figures 4.4(a) and 4.4 (b). 
 
(a) Mean rate of change for survivors (b) Mean rate of change for non-survivors 
  
Figure 4.4. Mean rate of change for )3(),2(),1( 3,21 TTT , (a) survivors; (b) non-survivors 
 
A similar situation is displayed in Figures 4.5(a) and 4.5(b) for the platelet count mean 
ratios. In this case, the mean ratios for 1T  were very similar in both datasets; however, after 
increasing the intervals ( 2T  and 3T ) the trend continued to be similar, but the means separated 
one from the other. The differences in mean ratio were between 0.20 and 0.87 for survivors and 
between 0.12 and 0.38 for non survivors. When using shorter time intervals, but starting at 75 
hours after the first platelet count measure, similar trends were observed.  Figures 4.6 and 4.7 
show the corresponding cases 1, 2, and 3 for the mean rate of change and the ratios calculated for 
4T , 5T and 6T , respectively.   
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(a) Mean ratio for survivors (b) Mean ratio for non-survivors 
  
Figure 4.5. Mean ratio for )3(),2(),1( 3,21 TTT , (a) survivors; (b) non-survivors 
 
(a) Mean rate of change for survivors (b) Mean rate of change for non-survivors 
  
Figure 4.6. Mean rate of change for )3(),2(),1( 6,54 TTT , (a) survivors; (b) non-survivors 
 
In Figures 4.6(a) and 4.6(b), the differences in mean rate of change were between 0.34 
and 1.37 for survivors and between 0.50 and 0.83 for non survivors. In Figures 4.7(a) and 4.7(b), 
the mean ratios over 4T  for survivors and non-survivors are almost the same. The differences in 
mean ratios were between 0.16 and 0.93 for survivors and between 0.004 and 0.31 for non 
survivors.  
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(a) Mean ratio for survivors (b) Mean ratio for non-survivors 
  
Figure 4.7. Mean ratio for )3(),2(),1( 6,54 TTT , (a) survivors; (b) non-survivors 
 
Figures 4.4 to 4.7 show that both datasets display the same trend in the mean rate of 
change and the mean ratio. However, the greatest similarity is seen for the mean ratio in 1T  and
4T . In the following section a statistical comparison of the mean rates of change and mean ratios 
for survivors and non-survivors is presented. 
4.1.3.1 Statistical Comparison of both Datasets 
Considering that, graphically, the mean ratios for 1T  and 4T  for survivors and non-
survivors were very similar in both datasets, two sample t-tests were conducted for the difference 
in mean ratios. The results were that 1T : p-value < 0.00001 for survivors and p-value=0.393 for 
non-survivors, and 4T : p-value < 0.00001 for survivors and p-value = 0.946 for non-survivors. 
Thus, it can be assumed that the mean ratios in 1T  and 4T  for non-survivors in both datasets are 
statistically the same. All differences between mean rates of change and mean ratios were tested 
statistically, and, in addition to the conclusions stated previously, the rates of change in 1T  (p-
value=0.393) and 4T  (p-value=0.406) for non-survivors in both datasets also was demonstrated 
to be statistically the same. Additionally, the ratio in 6T  (p-value=0.145) also showed no 
statistical differences between their means.   
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4.1.3.2 Classification Models 
Logistic regression models were constructed with all ratios and rates of change 
previously defined. Table 4.5 presents the parameter estimates, odds ratios, and corresponding 
95% CI for those estimates together with c-statistics for the best models. It can be observed that 
the best models for the VA dataset had a c-statistic of 0.78 for rates of change and ratios in 5T  
and 6T , whereas for the MIMIC II dataset, the maximum c-statistic was 0.64 with the model of 
platelet count ratios in 2T . The analysis of maximum likelihood estimates for the parameters and 
the likelihood ratio test for the models showed that all were significant (p-values<0.0001).  
 
Table 4.5. Best logistic regression models. iRc , jRc , rates of change; ir , jr , ratios 
    Intercept x Odds ratio c-statistic    Point estimate 95%CI 
VA dataset 
iRc  
2Rc  -1.189 -1.534 0.22 [0.11,0.41] 0.74 
3Rc  -0.880 -1.627 0.20 [0.10,0.38] 0.75 
ir  
2r  1.327 -2.214 0.11 [0.03,0.37] 0.75 
3r  1.317 -1.619 0.20 [0.08,0.50] 0.77 
jRc  
5Rc  -1.017 -1.408 0.25 [0.14,0.44] 0.78 
6Rc  -0.701 -1.556 0.21 [0.11,0.39] 0.78 
jr  
5r  2.118 -2.770 0.06 [0.02,0.24] 0.78 
6r  1.185 -1.586 0.21 [0.08,0.51] 0.78 
MIMIC II 
dataset ir 
2r  -0.033 -1.118 0.33 [0.18,0.59] 0.64 
3r  -0.401 -0.644 0.53 [0.33,0.84] 0.63 
 
Additionally, sensitivity analysis using bootstrapping with 100 replicates was conducted 
to observe the uncertainty of the parameter estimates. After repeating the sampling applying 
bootstrap, 95% CI for those estimates were calculated. All estimate values were inside the 
confidence intervals, suggesting the validity of the parameters. The results from this analysis are 
presented in Appendix A.  
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Ten-fold cross validation for all models was conducted. Table 4.6 shows the best models 
considering MSE and CV press for each dataset. It can be observed that the ratio and rate of 
change in 2T  showed a good result for the VA dataset with smaller MSE and CV press and also 
ratios in 3T  and 4T . However, for the MIMIC II dataset, the best models were obtained with the 
ratios in 2T  and 3T . 
 
Table 4.6. Best models from 10-fold cross validation. iRc , jRc , rates of change; ir , jr , ratios; 
MSE, mean square error; CV press, predicted residual sum of squares statistic 
   Intercept x CV press MSE 
VA dataset 
iRc  2Rc  0.194 -0.106 29.4 0.08 
ir  
2r  0.383 -0.155 17.5 0.09 
3r  0.390 -0.107 15.5 0.12 
jr  4r  0.384 -0.244 24.2 0.08 
MIMIC II 
dataset ir  
2r  0.380 -0.136 69.3 0.16 
3r  0.326 -0.071 52.3 0.17 
 
 Comparing the previous results from the two datasets, it can be concluded that metrics for 
intervals 2T  and 3T  showed the best results in terms of reduced MSE and CVpress. The next step 
was to repeat the methodology with other parameters from the VA dataset to evaluate the 
applicability of the methodology to other physiologic signals and then to evaluate if the inclusion 
of several parameters could enhance the predictive power of the models.     
4.1.4 Other Physiologic Parameters from the VA Dataset 
 The parameters available from the VA dataset were calcium, albumin, ionized calcium, 
and mean platelet volume (MPV). All these parameter values were measured during the same 
time interval as the platelet count values. However, a sample of only 308 patients had registered 
values for those parameters. The number of albumin tests registered accounted for only 15 
patients, and from them, only 8 ratios could be computed. Ionized calcium was registered for 
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only 13 patients, so this small sample was not taken into account. The final set of parameters to 
repeat the methodology was composed of mean platelet volume and calcium.    
4.1.4.1 Mean Platelet Volume Analysis 
 A total of 308 patients from the VA dataset were analyzed, including 289 survivors and 
19 non-survivors. This sample contained 7,758 MPV measures. The mean MPV was 8.38  0.90 
fL (95% CI = [8.36, 8.40]) and 8.25 1.01 fL (95% CI = [8.18,8.31]) for survivors and non-
survivors, respectively. Figure 4.8 shows the general behavior of the mean platelet volume over 
time.   
 
 
Figure 4.8. Mean platelet volume data over time - VA dataset 
  
 From Figure 4.8, the differences between survivors and non-survivors are not clear.  
Previous studies have concluded that high values of MPV are related with poor outcomes, but in 
specific diseases. For example, a study found that an increased MPV was independently related 
to a poor outcome in patients with acute ischemic cerebrovascular events [48], and another study 
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that analyzed platelet size in stroke patients [49] found that an increased MPV and a low levels 
in platelet count were features of both the acute and the non-acute phases of cerebral ischemia. 
Another study that analyzed increments in MPV in patients with chronic renal failure also 
concluded that “ larger platelets are more reactive and may contribute to an increased risk of 
thrombosis” [50].    
 Table 4.7 shows the logistic regression models for rates of change and ratios in intervals 
2T  and 3T . None of the models constructed for rates of change and ratios showed a significant c-
statistic, confirming the results of mean values previously presented, which were very similar 
between survivors and non-survivors and the behavior of MPV displayed in Figure 4.8.  
 
Table 4.7. MPV - Best logistic regression models for rates of change and ratios 
   Intercept x Odds ratio c-statistic    Point estimate 95%CI 
VA dataset 
iRc  
2Rc  -2.909 -23.420 0.0001 [<0.001,5.1860] 0.51 
3Rc  -2.895 -9.620 0.0001 [<0.001,>999.9] 0.53 
ir  2
r  -2.911 0.201 1.2220 [<0.001,>999.9] 0.44 
3r  -2.419 -0.323 0.7240 [<0.001,>999.9] 0.51 
 
 Two sample t-tests were also conducted to statistically verify if the models can 
differentiate survivors from non-survivors. As a result, none of the models could make the 
differentiation (0.36<p-values<0.95). This result is supported by low c-statistics less than 0.53. 
Appendix A provides complete descriptive statistics and p-values for the differences in mean for 
both metrics, ratios and rates of change.  
4.1.4.2 Calcium Analysis 
 A total of 308 patients from the VA dataset were analyzed, including 289 survivors and 
19 non-survivors. This sample contained 8,047 calcium measures. The mean calcium value was 
8.76  0.79 mg/dL (95% CI = [8.74, 8.78]) and 8.64 10.77 mg/dL (95% CI = [8.59,8.69]) for 
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survivors and non-survivors, respectively. Figure 4.9 shows the general behavior of the calcium 
data over time, where differences between survivors and non-survivors were notable. An 
increasing trend for survivors can be seen, whereas for non-survivors, the calcium values do not 
show any specific trend.  
 
  
Figure 4.9. Calcium data over time - VA dataset 
 
 According to the National Institute of Health, the reference range for calcium is from 8.5 
to 10.2 mg/dL [51]. As shown, most of the patients, both survivors and non-survivors, presented 
calcium values that were lower than the minimum normal level, even 300 hours (~12 days) after 
the date of the surgery. This issue provides signs of hypocalcemia, which is a common finding in 
critically-ill patients [52]. Nevertheless, it can also be observed that there are some patients with 
normal levels after 200 hours who did not survive. This situation could be due to possible post-
surgical complications, which are not addressed in this research.  
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 We need to consider that, although the VA dataset is composed of patients who 
underwent similar cardiac surgeries, each patient has a different condition and his/her organism 
reacts different to the intervention and treatment.   
 Table 4.8 shows the logistic regression models for the rates of change and ratios for 
intervals 2T and 3T . The results for models constructed with rates of change were better (0.79  c
 0.80) than the results for the models constructed with calcium ratios (0.66  c 0.72). This 
result is similar to the result observed for platelet count in this population, where rates of change 
performed better than ratios, but in shorter intervals starting up 75 hours ( 5T and 6T .) However, 
platelet count ratios performed equal to or better than the rates of change for the same intervals 
2T and 3T . Two sample t-tests showed that only rates of change for 1T and 2T  could differentiate 
survivors from non-survivors; the other metrics could not (0.14< p-values<0.79). Appendix B 
provides complete descriptive statistics and p-values for the differences in mean for both metrics 
ratios and rates of change. 
 
Table 4.8. Calcium - Best logistic regression models for rates of change and ratios 
    Intercept x Odds ratio c-statistic    Point estimate 95%CI 
VA dataset 
iRc  
2Rc  -2.592 -96.238 <0.001 [<0.001,<0.001] 0.80 
3Rc  -2.554 -113.800 <0.001 [<0.001,<0.001] 0.79 
ir  2
r  3.804 -6.181 0.0020 [<0.001,1.7170] 0.66 
3r  6.888 -9.195 0.0001 [<0.001,1.3900] 0.72 
 
 Two sample t-tests showed that only rates of change for 1T and 2T  could differentiate 
survivors from non-survivors; the other metrics could not (0.14< p-values<0.79). Appendix B 
provides complete descriptive statistics and p-values for the differences in mean for both metrics 
ratios and rates of change. 
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 Considering that the ten-fold cross validation in Section 4.1.3.2 showed that ratios in 2T  
and 3T  had the best results in both datasets, a preliminary analysis was conducted with 2r 	. The 
physiologic parameters considered were platelet count, calcium, and mean platelet volume. 
4.1.4.3 Preliminary Multivariate Analysis using 2r   
 The VA dataset with values for ratios 2r  for platelet counts, calcium, and mean platelet 
volume were used for the analysis. The sample was composed by 126 patients, including 8 non-
survivors. To visualize the differences between survivors and non-survivors, surface plots are 
shown in Figure 4.10 and contour plots are shown in Figure 4.11.  
 The surface plots show that ratios of platelet count were higher for survivors than non-
survivors. Figure 4.11 better demonstrates the differences in platelet count and calcium ratios for 
survivors and non-survivors. More survivors had higher ratios of platelet count that were more 
than 2 and calcium ratios that are more than 1, whereas the majority of non-survivors had platelet 
count ratios less than 1.6. 
 
 
 
Figure 4.10. Surface plots of ratios in 2T with PLT 2r , Ca 2r and MPV 2r  
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Figure 4.11. Contour plots of ratios in 2T  with PLT 2r , Ca 2r and MPV 2r  
 
 Figure 4.11 shows that, in the plane formed by MPV and calcium ratios in 2T , the 
biggest region observed for survivors is given by ratios of platelet count that were between 1.5 
and 2, whereas the biggest region for non-survivors is given by ratios of platelet count between 
1.2 and 1.6.   
 Table 4.9 shows the logistic regression model for ratios in 2T : platelet count, calcium and 
MPV. The c-statistic for the model was 0.748, and the smaller odds ratio was for the calcium 
ratio. 
Table 4.9. PLT, Ca and MPV ratios in 2T - Best logistic regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 14.984 -  
PLT 2r  -1.6673 0.189 [<0.001, 0.910] 
Ca 2r  -8.9479 <0.001 [<0.001,274.1] 
MPV 2r  -5.7314 0.003 [0.026, 1.383] 
c-statistic 0.748   
  
 As presented in Section 3.4.1, the mean platelet volume was a surrogate for the platelet 
age and, combined with the platelet count, allows the estimation of platelet mass. Using the same 
VA dataset of 308 patients and equation (1) from Chapter 3, platelet mass was estimated. This 
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sample contained 6,927 platelet mass values. The mean platelet mass was 1842.9 892.5x10-6 
(95% CI = [1820.6,1865.1] x10-6) and 1643.1 737.3 x10-6 (95% CI = [1599.5,1696.8]x10-6) for 
survivors and non-survivors, respectively. Repeating the methodology previously described, the 
behavior of platelet mass is shown in in Figure 4.12. 
  
 
Figure 4.12. Platelet mass data over time - VA dataset 
  
 In this figure we can observe that the trends in survivors differ from the trends in non-
survivors. As observed for the calcium and platelet count, the platelet mass showed an increasing 
trend for survivors. Ratios and rates of change were computed for platelet mass, and the best 
logistic regression models with this parameter for both metrics in 2T and 3T  were constructed. 
Table 4.10 shows the estimates for the models; the best c-statistic (c=0.78) was calculated for the 
rate of change in 3T . 
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Table 4.10. PLT mass - Best logistic regression models. iRc , jRc , rates of change; ir , jr , ratios 
   Intercept x Odds ratio c-statistic    Point estimate 95%CI 
VA dataset 
iRc  
2Rc  -2.3882 -0.0872 0.91 [<0.001,<0.001] 0.77 
3Rc  -2.0883 -0.1334 0.87 [<0.001,<0.001] 0.78 
ir  2
r  -0.8533 -1.2052 0.30 [<0.001,1.7170] 0.69 
3r  -1.0698 -0.9069 0.40 [<0.001,1.3900] 0.71 
 
 Two sample t-tests between mean rates of change and mean ratios showed that only the 
rates of change for 1T  and 2T  and the ratios for 2T  could differentiate survivors from non-
survivors; the other metrics could not (0.098< p-values<0.20). Appendix A provides complete 
descriptive statistics and p-values for the differences in mean for both metrics, ratios and rates of 
change. 
  If these results are compared with the previous results obtained for platelet counts in 
terms of c-statistic, it can be concluded that the use of platelet mass improves the predictive 
power of the rate of change. The c-statistic for 2Rc  (rate of change in interval 2T ) improved from 
0.74 to 0.77 and for 3Rc (rate of change in interval 3T ) improved from 0.75 to 0.78. However, the 
c-statistic for the ratio 2r  decreased from 0.75 to 0.69 and for 3r decreased from 0.77 to 0.71.   
Considering the improvement of the results using platelet mass, compared to the results 
using platelet count values, a preliminary analysis combining calcium and platelet mass in 2T  
was conducted. Figure 4.13 shows a scatter plot from rates of change of calcium and platelet 
mass. In this figure we can observe a trend of higher platelet values and higher calcium values 
(positive trend) for survivors. However, a clear decrement of those parameters (negative trend) is 
shown for non-survivors. This issue confirms that the recovery process is different in survivors 
and non-survivors. 
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Figure 4.13. Platelet mass and calcium rates of change in 2T - VA dataset 
 
Table 4.11 shows the best logistic regression model for platelet mass and calcium rates of 
change. The predictive power of the model increased (c=0.834). However, the calcium parameter 
was more significant, with a very high estimate compared to the platelet mass. 
 
Table 4.11. PLT mass and Ca rates of change in 2T - Best logistic regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -2.448 -  
PLT mass 2Rc  -0.038 0.963 [0.892, 1.039] 
Calcium 2Rc  -78.8 <0.001 [<0.001, <0.001] 
c-statistic 0.834   
 
 Since the ratios in 2T  showed better results for the MIMIC II dataset, this metric was also 
analyzed. Figure 4.14 shows the behavior of the ratios for 2T . It can be observed that the 
relationship between ratios for platelet mass and calcium in 2T  had a positive trend for survivors.  
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Figure 4.14. Platelet mass and calcium ratios in 2T - VA dataset  
  
 Although an increasing trend is shown for survivor, for non-survivors, there was not a 
notable relationship. Of note is that the sample size for non-survivors was reduced to eight; the 
results for non-survivors are inconclusive. Table 4.12 shows the best regression model using 
platelet mass and calcium ratios. It can be observed that the platelet mass had a higher impact in 
the regression model, and the c-statistic was lower than the statistics for the rate of change using 
the same parameters.  It can be concluded that the predictive power of the model decreases using 
ratios instead of rates of change, but since the objective was to extend the methodology to a 
broader population, the ratios were considered for the next step.  
 
Table 4.12. PLT mass and Ca ratios in 2T - Best logistic regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 5.40 -  
PLT mass 2r  -0.69 0.497 [0.103, 2.399] 
Calcium 2r  -6.7 0.001 [<0.001, 8.282] 
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 At this point in the study, the multivariate analysis considered each parameter 
independently and how it directly affects the patient outcome. However, how the addition of 
interaction terms in the model could improve the results must be evaluated. Therefore, 
interaction terms were added in both models from Table 4.11 and Table 4.12. The results showed 
a slight improvement in the value of the c-statistic. In the case of the model for rates of change, 
the addition of an interaction term between platelet mass rate of change and calcium rate of 
change increased the c-statistic from 0.83 to 0.86. The analysis of maximum likelihood showed 
that the interaction term was significant (p-value=0.006). Similarly, in the case of the ratios, the 
interaction term improved the c-statistic from 0.75 to 0.77. However, in this case, the analysis of 
maximum likelihood showed that the interaction term was not significant (p-value=0.132). The 
complete regression model including all the terms and estimates is presented in Appendix C. 
4.1.5 Analysis of Other Parameters from the MIMIC II Dataset 
 From the previous section, it was determined that calcium and platelet mass can provide 
prognostic information. The MIMIC II dataset contains information about different laboratory 
tests. However, the focus herein will continue to be on hemodynamic parameters. The 
methodology is repeated using the calcium tests from the MIMIC II dataset and other 
parameters. As defined previously, other parameters that could be included are albumin, anion 
gap, and total CO2. In the case of platelet mass, the MIMIC II dataset does not contain 
information regarding mean platelet volume; thus, an estimation of platelet mass is not possible.   
 The behavior of calcium was analyzed so a comparison with the VA dataset could be 
conducted. Then, the methodology applied to albumin, total carbon dioxide, and anion gap was 
repeated. After analyzing each parameter independently, they were combined and the impact of 
those combinations was assessed.   
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4.1.5.1 Calcium Analysis – MIMIC II Dataset 
 A total of 1,650 patients from the MIMIC II dataset were analyzed, including 802 
survivors and 848 non-survivors. Those patients had at least two measures registered during the 
period of analysis. This sample contains 1,660 admission cases and 11,781 measures. The mean 
calcium values were 8.37  0.76 mg/dL (95% CI = [8.35, 8.39]) and 8.28  0.78 mg/dL (95% CI 
= [8.27,8.30]) for survivors and non-survivors, respectively. It was observed that the mean values 
were very similar for both survivors and non-survivors. Nevertheless, the confidence intervals 
calculated for the means did not overlap; thus it can be concluded that, on average, survivors 
have higher mean calcium levels than non-survivors.  
 Figure 4.15 displays the general behavior of the calcium data over time for 30 admission 
cases (i.e. combination between ICU admission and patient).  
 
 
Figure 4.15. Calcium data over time - MIMIC II dataset 
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 As seen for the calcium data from the VA dataset, the calcium levels for survivors and 
non-survivors decreased during the first 100 hours. Most of the calcium levels dropped below 8.5 
mg/dL, the lower limit for a “normal” range [50], an issue that confirms that hypocalcemia is 
commonly presented in critically-ill patients [40].  
 Figure 4.15 shows that the drop in calcium level for survivors was not as abrupt as the 
drop for non-survivors and that the recovery of survivors could be seen during the first 150 hours 
after the reference event. However, the behavior of calcium levels in non-survivors did not show 
a specific pattern, since calcium levels in some cases were over the lower normal limit of 8.5 
mg/dL [50].  
Table 4.13 presents the logistic regression models for the calcium ratios and rates of 
change. The table shows that the results for calcium levels with the MIMIC II dataset varied 
from the results obtained with the VA dataset. The c-statistics for the models with the ratios and 
the rates of change, based on the MIMIC II dataset, were lower (c 0.60) than the c-statistics for 
the models obtained using the VA dataset (0.66 c  0.80).  All odds ratio estimates were higher 
than the estimates found for the VA dataset, where the odds ratio estimates were less than 0.001. 
However, as seen before for the platelet count in the intervals 1T and 2T , the ratios provided better 
results than the rates of change. 
 
Table 4.13. Logistic regression models for calcium. iRc , rates of change; ir , ratios 
    Intercept x Odds ratio c-statistic    Point estimate 95%CI 
MIMIC II 
dataset 
iRc  
1Rc  0.3006 0.5557 1.743 [0.005,579.58] 0.47 
2Rc  0.2151 1.0074 2.738 [0.120,62.305] 0.46 
3Rc  0.1799 1.3587 3.891 [0.093,162.13] 0.45 
ir  
1r  0.7082 -0.5204 0.594 [0.047,7.524] 0.53 
2r  1.2476 -0.978 0.376 [0.032,4.358] 0.56 
3r  2.3719 -2.0547 0.128 [0.007,2.361] 0.60 
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 Two sample t-tests between mean rates of change of survivors and non-survivors, as well 
as between mean ratios, did not show statistical differences between means (0.148<p-values 
<0.85). This result suggests that both metrics based on calcium values could not differentiate 
survivors from non-survivors. It is important to note that, although no statistical differences 
could be found between survivors and non-survivors using these metrics, there is a clear 
difference in the recovery process of survivors and non-survivors, as shown in Figure 4.15. In 
this figure we observed that the calcium level for survivors recover very quickly during the first 
150 hours after the reference event.   
 The next step was to analyze other parameters that have shown, through previous studies, 
to have any prognostic significance among ICU or critically-ill patients. As stated in Chapter 2, 
there are other physiologic parameters measured through blood tests (albumin, anion gap, and 
total carbon dioxide) that vary their behavior in patients with acute illnesses. Those parameters 
were analyzed individually and then together to determine if the hidden interaction between them 
can provide more information regarding the patient outcome. 
4.1.5.2 Albumin Analysis – MIMIC II Dataset 
 A total of 676 patients from the MIMIC II dataset were analyzed, including 270 survivors 
and 406 non-survivors. This sample contained 680 admission cases and 2,305 measures. The 
mean albumin values were 2.94 0.71 g/dL (95% CI = [2.90, 2.99]) and 2.64 0.59 g/dL (95% 
CI = [2.61, 2.67]) for survivors and non-survivors, respectively. As seen for the mean calcium 
levels, the mean albumin levels show differences between survivors and non-survivors. It can be 
seen that the confidence intervals for the mean values did not overlap, and on average, albumin 
levels for non-survivors were lower than albumin levels for survivors. Figure 4.16 shows the 
general behavior of the albumin data over time for a sample of 30 admission cases.  
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Figure 4.16. Albumin data over time - MIMIC II dataset 
 
 In the previous figure we cannot observe notable differences between survivors and non-
survivors. Nevertheless, more variation in the albumin level was present for survivors. 
According to the National Institute of Health, the reference range for albumin is from 3.4 to 5.4 
mg/dL [53]. In Figure 4.16, the majority of the patients, both survivors and non-survivors, had 
albumin values lower than the normal lower limit, which suggests the presence of albuminemia. 
This behavior confirmed that low albumin levels were presented in critically-ill patients [54].   
 Table 4.14 shows the best regression models for the albumin ratios and rates of change.  
Although the c-statistics for the ratios in 21,TT , and 3T showed better results (0.58  c  0.79) 
than the statistics for the rates of change (0.39  c  0.52)  in the same intervals, the sample sizes 
of the ratios for this parameter were smaller than the sample sizes for the same metric applied to 
other parameters, where at least 200 values for the ratios were used for analysis. In this case, the 
sample sizes for the ratios with albumin were, 18, 17, and 10 for 1r , 2r and 3r , respectively. 
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Therefore, the results were not conclusive and more data will need to be available to make any 
statement regarding this parameter. .Is important to note that the measure of albumin is not 
common and that a similar situation was found with the VA dataset. In that case the sample size 
of albumin only allowed the calculation of 8 ratios, because only 15 patients had albumin values 
registered.   
 
Table 4.14. Logistic regression models for albumin. iRc , rates of change; ir , ratios 
   Intercept x Odds ratio c-statistic    Point estimate 95%CI 
MIMIC II 
dataset 
iRc  
1Rc  0.6124 4.9879 146.6 [<0.001, >999] 0.39 
2Rc  0.5848 16.476 >999 [<0.001, >999] 0.52 
3Rc  0.6188 9.658 >999 [<0.001, >999] 0.46 
ir  
1r  -0.1843 0.8435 2.324 [0.030,181.582] 0.58 
2r  8.8479 -8.3005 <0.001 [<0.001, >999] 0.63 
3r  -8.6031 8.6340 >999 [0.055, >999] 0.79 
 
Two sample t-tests between mean rates of change and mean ratios showed that none of 
them can differentiate survivors from non-survivors (0.09< p-values<0.71). This result may be 
due to the high variability presented in the albumin values and confirmed that the albumin levels 
in critically-ill patients did not show notorious differences between survivors and non-survivors, 
as was shown in Figure 4.16.  
4.1.5.3 Total CO2 Analysis – MIMIC II Dataset 
 A total of 1,685 patients from the MIMIC II dataset were analyzed, including 843 
survivors and 842 non-survivors. Those patients had at least two measures registered during the 
period of analysis. This sample contained 1,697 admission cases and 16,120 measures. The mean 
TCO2 value was 24.94  4.27 mEq/L (95% CI = [24.84, 25.04]) and 24.42  5.29 mEq/L (95% 
CI = [24.31, 24.53]) for survivors and non-survivors, respectively. Figure 4.17 shows the general 
behavior of the TCO2 data over time for a sample of 30 admission cases.   
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Figure 4.17. Total CO2 data over time - MIMIC II dataset 
  
 In Figure 4.17 we cannot observe a clear difference between survivors and non-survivors. 
However, some of the non-survivors had TCO2 values less than 23 mEq/L, the lower limit for the 
common “normal” range [44].  
 Table 4.15 shows the best regression models for the ratios and rates of change applied to 
total CO2. It can be seen that the c-statistics for all models with total carbon dioxide were smaller 
than the statistics with calcium or platelet count applied to the same dataset.  
 
Table 4.15. Logistic regression models for TCO2. iRc , rates of change; ir , ratios 
   Intercept x Odds ratio c-statistic    Point estimate 95%CI 
MIMIC II 
dataset 
iRc  
1Rc  0.0961 -0.0914 0.913 [0.383,2.177] 0.51 
2Rc  0.0971 -0.7499 0.472 [0.099,2.255] 0.51 
3Rc  0.0900 -0.9573 0.384 [0.069,2.133] 0.50 
ir  
1r  0.5933 -0.3884 0.678 [0.260,1.770] 0.51 
2r  0.7472 -0.4667 0.627 [0.220,1.784] 0.52 
3r  0.8132 -0.4470 0.640 [0.240,1.706] 0.54 
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 The best results shown in Table 4.15 were for ratios in 2T  and 3T , where c-statistics were 
0.52 and 0.54, respectively. Two sample t-tests between mean rates of change and mean ratios 
showed that none of the metrics can differentiate survivors from non-survivors (0.27< p-
values<0.83). 
It is important to note that the measure of total carbon dioxide is usually accompanied 
with the computation of the anion gap, since together they provide physicians with more 
information to diagnose or treat any acid-base imbalance. The most common disorder is 
metabolic acidosis, which usually occurs if the body produces too much acid or loses too much 
bicarbonate. Acidosis is reflected in the low pH level of blood and tissues. In the next sub-
section, the anion gap is analyzed to evaluate if this parameter can provide prognostic 
information. This and other implications derived from the analysis of anion gap levels and low 
total carbon dioxide is discussed in Section 4.2.    
4.1.5.4 Anion Gap Analysis – MIMIC II Dataset 
 A total of 1,564 patients from the MIMIC II dataset were analyzed, including 789 
survivors and 775 non-survivors. Those patients had at least two measures registered during the 
period of analysis. This sample contained 1,575 admission cases and 14,943 measures. The mean 
anion gap value was 13.6 3.21 mEq/L (95% CI = [13.53, 13.68]) and 14.61  4.01 mEq/L 
(95% CI = [14.52, 14.70]) for survivors and non-survivors, respectively. From the data, it can be 
seen that the means between survivors and non-survivors were different. Both confidence 
intervals for the means did not overlap. Therefore, it can be concluded that, on average, anion 
gap values for non-survivors were higher than the anion gap values for survivors. Figure 4.18 
shows the general behavior of the anion gap data over time for 30 admission cases.  
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Figure 4.18. Anion gap data over time - MIMIC II dataset 
  
 The previous figure shows differences between survivors and non-survivors. First, non-
survivors usually presented higher anion gap values than survivors. Second, the variability in 
non-survivors was higher than the variability presented in survivors.  
 In general, it also was seen that several patients had anion gap values greater than 16 (the 
upper limit for common “normal” ranges, estimated by colorimetric and flame photometry), an 
issue that suggests the presence of acidosis. Nevertheless, there were also patients that did not 
have “abnormal” anion gaps but did not survive. In the previous sub-section, total carbon dioxide 
was analyzed, and it was observed that most of the non-survivors showed low levels of carbon 
dioxide, whereas in Figure 4.18, it was observed that most of the non-survivors showed high 
anion gaps. This situation of having low levels of carbon dioxide (less than 23 mEq/L) and high 
levels of anion gap (more than 16 mEq/L) suggests the presence of a severe acidosis with 
increased anion gap, an illness that could be life-threatening. 
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 Table 4.16 shows the results from the best regression models for the anion gap, where c-
statistics were lower than the statistics with other parameters such as calcium and platelet count 
applied to the same dataset. However, the results in terms of c-statistic for the anion gap ratios 
and rates of change were very similar (0.55 c 0.57).  
 
Table 4.16. Logistic regression models for anion gap. iRc , rates of change; ir , ratios 
   Intercept x Odds ratio c-statistic    Point estimate 95%CI 
MIMIC II 
dataset 
iRc  
1Rc  0.0953 -1.533 0.216 [0.076,0.611] 0.56 
2Rc  0.0793 -1.6601 0.190 [0.037,0.972] 0.55 
3Rc  0.0767 -1.0403 0.352 [0.059,2.120] 0.56 
ir  
1r  1.2424 -1.0318 0.356 [0.161,0.790] 0.57 
2r  1.1648 -0.8835 0.413 [0.169,1.009] 0.55 
3r  0.9750 -0.7040 0.495 [0.197,1.243] 0.56 
 
 Two sample t-tests between mean rates of change and mean ratios showed that ratios and 
rates of change for the intervals 1T  and 2T can differentiate survivors from non-survivors, but the 
metrics in the interval 3T could not, with p-value=0.134 for the ratio and p-value=0.243 for the 
rate of change. This result indicates that in intervals from 50 to 150 or 50 to 200 hours (between 
4 and 6 days), the differences in anion gap between survivors and non-survivors were more 
notorious. It can also be seen that the odds ratio estimates in interval 3T for both metrics, ratios 
and rates of change, were higher than the odds ratio estimates from the models developed for the 
same metrics in smaller intervals.  
 Appendix B provides the complete descriptive statistics and p-values for the differences 
in mean ratios and mean rates of change for all the parameters described in the current section. 
After reviewing the results for each parameter individually with the MIMIC II dataset, it can be 
seen that, although some of them show differences between survivors and non-survivors, the 
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results in terms of concordance measures was not as significant as the results obtained with the 
platelet count. In the following section, the impact of including simultaneously several 
parameters and their interactions in the results of the regression models are analyzed.  
4.1.6 Multivariate Analysis – MIMIC II Dataset 
 From the previous sections, it was observed that none of the parameters performed as 
well as platelet count. However, the inclusion of some parameters simultaneously while 
analyzing the VA dataset showed that the predictive power of the models could be improved. 
Additionally, the results from the MIMIC II dataset suggested that ratios in 2T and 3T  performed 
better than rates of change. The impact in using simultaneously different parameters were 
analyzed with ratios for 2T  and 3T . Table 4.17 shows the c-statistics and sample sizes for each 
regression model for ratios in 2T  and 3T  depending on the parameters included. From 26 possible 
models, considering the combination of 2, 3, 4 and 5 parameters, only 11 had sample sizes 
greater than 18; the other models had sample sizes lower than 6, which does not allow the 
development of a reliable model.  
Table 4.17. C-statistics and sample sizes for models with ratios ir  
Parameters in the model 2r  3r  
 Sample size c-statistic Sample size c-statistic 
PLT, Ca 82 0.618 56 0.569 
PLT, AG 127 0.633 87 0.614 
PLT, TCO2 42 0.642 92 0.590 
TCO2, AG 31 0.701 53 0.604 
PLT, Ca, TCO2 22 0.924 37 0.765 
Ca, TCO2, AG 18 0.854 25 0.715 
PLT, Ca, AG, TCO2 18 0.889 25 0.760 
Ca, TCO2 22 0.848 37 0.718 
Ca, AG 51 0.671 38 0.623 
PLT, Ca, AG 51 0.662 38 0.694 
PLT, TCO2, AG 31 0.707 53 0.636 
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 The first seven models presented for ratios in 2T  were statistically valid and some of their 
parameters were significant; the analysis of maximum likelihood estimates showed significance 
for some of the parameters (p-value<0.06), and the global null hypothesis testing (Chi-square 
test) also showed significance (p-value<0.06). However, the last four models did not show 
significance nor did the models developed with ratios in 3T .  
 Throughout the previous results, it can be seen that the inclusion of some parameters in 
the model enhanced its performance in terms of the c-statistic—being the best model, which 
includes platelet count, calcium, and total carbon dioxide (c=0.92). Figure 4.19 presents the ROC 
curve for this model. It can be seen that the curve follows the left-hand border and then the top 
border, showing the accuracy of the classification model.  
 
 
Figure 4.19. ROC curve for the model with Ca, PLT and TCO2 - MIMIC II dataset  
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 The maximum likelihood ratio for this model presented a p-value=0.002, whereas the 
different estimates vary, with calcium (p-value=0.02) the most significant. Carbon dioxide (p-
value=0.07) and platelet count (p-value=0.07) may be not significant at 5%.  
 A similar situation was observed for the model that includes platelet count, calcium, 
anion gap, and total CO2. The maximum likelihood ratio presented a p-value=0.02, and the most 
significant parameter was calcium (p-value=0.05), but the other parameters were not statistically 
significant (0.1 p-value 0.39). When analyzing the model with calcium, anion gap, and total 
carbon dioxide, then the maximum likelihood ratio showed a p-value of 0.06, but all the 
estimates were not significant (0.1 p-value  0.18). It can be concluded that although the c-
statistic may be improved considering several parameters simultaneously in the model, the 
inclusion of those parameters in the model may not necessarily be significant. Appendix D 
provides the models developed, including the parameters estimates, point estimates, and 95% CI 
for the odds ratios. 
In Section 4.1.4.3, modeling was discussed by analyzing various parameters 
simultaneously and as well as the impact of adding interaction terms into those models. It was 
concluded in the case of rates of change that the performance of the model was improved. 
Therefore, the best models were selected from Table 4.17 and the models interaction terms were 
developed.  
 First, the model that includes platelet count, calcium, and total carbon dioxide was 
selected, because it was the model that provided a better c-statistic. However, the maximum 
likelihood estimates could not be computed because the data points were separated.  Second, the 
model that includes platelet, calcium, total carbon dioxide, and anion gap was selected, and the 
results were similar. No maximum likelihood estimates could be computed. Third, the model 
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with calcium, total carbon dioxide, and anion gap was reviewed. In this case, the c-statistic was 
improved from 0.85 to 0.86. However, the analysis of maximum likelihood showed that none of 
the interactions were significant (p-value 0.32). Finally, the model that includes calcium and 
total carbon dioxide was selected. In this case, the c-statistic improved from 0.84 to 0.85, but, 
again, the interaction term was not significant (p-value=0.33). It can be concluded that the 
interaction terms in the classification models do not add value to the result. Appendix C presents 
the complete regression models from these cases.  
 In the present analysis of various parameters, the sample sizes were too small to apply the 
bootstrapping methodology to evaluate the sensitivity of the estimates. In the following section, 
the results are discussed and compared with the results obtained by previous similar studies. The 
platelet count analysis is discussed first, comparing the results from both datasets. The addition 
of other parameters and the corresponding multivariate analysis with the VA dataset is then 
reviewed. Finally, other parameters from the MIMIC II dataset were also analyzed, individually 
and simultaneously. A discussion of these results and their impact in patient monitoring is 
presented.  
 
4.2 Discussion 
4.2.1 Platelet Count Analysis  
The data mining approach conducted has shown the changes over time of the platelet 
count for two different cohorts: a homogeneous population from the VA dataset and a 
heterogeneous population composed of ICU patients from different hospitals, conditions, and 
diseases. Both datasets were selected, because the objective is to generalize the methodology to 
the broader and heterogeneous population. Both datasets were compared using two metrics: rate 
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of change as determined by multiple point regression and by the simpler fixed-time platelet value 
ratios at specific time intervals. Both datasets demonstrated that the metrics (rates of change and 
ratios) are comparable and can differentiate survivors from non-survivors, and, moreover, that 
the results are comparable. That means that a simple fraction between two specific measures can 
be used to estimate the probability of having an adverse event, providing a warning that could 
aid the physicians’ decision making process.  
The result in terms of concordance measures (c-statistic) for the homogeneous population 
was better than other results found in the literature using other similar metrics and even risk 
assessment scores that involved several other parameters, not only related to the circulatory 
system, but also to respiratory, nervous, and cardiovascular systems, among others. Most of 
those risk scores use at least 12 parameters [34, 57]. It is important to note that several studies 
suggest that thrombocytopenia in critically-ill patients is a marker of illness severity, and some 
risk assessment scores (e.g., SOFA or APACHE II) support this issue by reporting higher scores 
in these types of patients than in patients who were admitted with normal platelet values to the 
ICU [47]. The c-statistics from the models with the MIMIC II dataset were lower than the c-
statistics from the VA dataset, as would be expected due to the heterogeneity and variability 
presented in the data.   
The time intervals were chosen after observing that platelet counts fall promptly after an 
acute event and then variably return toward a normal level, allowing an important marker to be 
defined for this critical episode of the care cycle. The biphasic course observed in this study has 
been reported in previous studies that studied patients after surgery [55] and patients with acute 
myocardial infarction [56]. The upper limit of the intervals used for the analysis was 200 hours 
(approximately 8 days). Longer intervals were not used because they were not considered 
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prognostically useful for a timely intervention or decision early in a patient’s care cycle. 
However, time in clinical decision-making for critically-ill patients is vital, and the use of a 
single metric as a ratio of values at two time points could be more beneficial in this setting. Thus, 
it has been demonstrated that the ratios using only 2 measures over a specific interval, such as 75 
to 150 or 75 to 200 hours (~3 to 5 days), can provide prognostic information comparable to using 
the formal rate of change over the same interval.   
After statistically comparing both datasets, it can be concluded that the models for the 
ratios in 2T (50 to 150 hours) and 3T  (50 to 200 hours) show the best performance for the MIMIC 
II dataset and a very good performance for the VA dataset. Therefore, the ratios for 2T and 3T  can 
be used to analyze changes over time in platelet count, providing a dynamic patient profile that 
may improve the management of these complex processes. It also has been demonstrated that 
ratios in 5T (75 to 150 hours) and 6T  (75 to 200 hours) can discriminate outcomes as well as the 
rate of change in a homogeneous population  (the VA dataset), both having a c-statistic of 0.78. 
This result is better than the result from APACHE II score (c=0.72), the rate of change per day 
(c=0.74) analyzed by Nijsten et al. [32], and the results from Strauss et al. [47], who used a drop 
in platelet count percentage as metric in a prospective study (c=0.75) and compared the results 
with APACHE II (c=0.73) and the Sequential Organ Failure Assessment score - SOFA (c=0.73) 
[56].  
4.2.2 Multivariate Analysis – Platelet Count, Calcium and MPV- VA Dataset 
 First, mean platelet volume was analyzed independently and was found to have none of 
the metrics that could differentiate survivors from non-survivors. Also, the c-statistics from the 
prediction models were very low (c 0.53). However, 95% CI for the mean values did not 
overlap, suggesting that there should be a difference between MPV values of survivors and non-
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survivors. Additionally, calcium was analyzed independently and differences were seen between 
survivors and non-survivors. Although the mean values were similar, an increasing trend for 
survivors was seen, while almost a plateau was seen for non-survivors.  After comparing the 
models developed for the metrics, the best results were for rates of change for 2T (c=0.79) and 3T
(c=0.80), differentiating both survivors from non-survivors.   
Using platelet count, calcium, and mean platelet volume, a first multivariate analysis was 
conducted with the ratio for 2T  (c=0.75).  This result was similar to the result obtained for 
platelet count and better than the result obtained independently for calcium and mean platelet 
volume using the same ratio.  
Mean platelet volume was combined with platelet count as platelet mass. As a result, the 
behavior of platelet mass between survivors and non-survivors showed more differences; 95% CI 
for the mean platelet mass was [1820.6,1865.1] x10-6 and [1599.5,1696.8]x10-6 for survivors and 
non-survivors, respectively. It can be concluded that the use of platelet mass highlights the 
differences between survivors and non-survivors and may be a good marker to consider if the 
measure of mean platelet volume is available.  
The methodology was first applied for platelet mass independently, improving the results 
with respect to the results from the platelet count using the rates of change for 2T (c=0.77) and 3T
(c=0.78). The multivariate analysis was conducted again using calcium and platelet mass. The 
results were improved for the rate of change in 2T (c=0.83) and ratio in 2T (c=0.75). From these 
results, it can be concluded that the combination of platelet count and mean platelet volume 
enhances the performance of the models and that the application of the same methodology with 
calcium and mean platelet mass may improve the predictive power of the models in a 
homogenous population as the VA dataset.   
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Finally, interaction terms were added into the classification models and, as a result, in 
both cases, rates of change and ratios, the c-statistic was improved. However, only in the case of 
the rate of change was the interaction term significant, and its inclusion as part of the 
classification model should be considered. In the following section, the results obtained with the 
MIMIC II dataset are discussed.  
4.2.3 Analysis of other Parameters - MIMIC II Dataset  
The methodology to analyze other parameters from the MIMIC II dataset was applied to 
calcium, albumin, anion gap and total CO2. Those parameters have shown, through previous 
studies, that they could influence clinical outcomes in critically-ill patients. As reviewed in 
Chapter 2, several conditions, such as hypocalcemia, metabolic acidosis, or hypoalbuminemia, 
are present in ICU patients. In this study, each of those parameters was analyzed independently 
and then simultaneously. Predictive models with each parameter were constructed and assessed, 
and then models with more than one parameter were constructed and analyzed.   
The behavior of the calcium values using the MIMIC II dataset was similar to the 
behavior seen with the homogeneous dataset from the VA. However, the differences between 
survivors and non-survivors were not as notable as for the VA population. In all cases, a drop 
was seen (calcium values less than 8.5 mg/dL), but the lowest calcium levels were seen for non-
survivors. The recovery regarding calcium levels for survivors was quicker than the recovery for 
non-survivors. The result confirms the results obtained from previous studies that have used 
calcium as a marker for anticipating patient outcome. In this heterogeneous population, 
independent of the disease, the drops for non-survivors are lower than 8 mg/dL, which confirms 
the result from Zilvin et al. [40], who found that hypocalcemia (low levels of calcium) was 
present in around 88% of the patients included in his study. His sample was composed of 99 
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patients admitted to 7 different ICUs (medical, surgical, and burn, among others), but his study 
could not find a correlation between hypocalcemia and any specific illness. He only concluded 
that the hypocalcemia correlates with the severity of the illness.   
Albumin was analyzed. The behavior of the albumin values did not show a notorious 
difference between survivors and non-survivors. However, mean values for non-survivors were 
lower than the mean values from survivors, indicating that the risk of complications is higher 
when albumin levels are low [36]. A similar situation was seen in a study conducted with elderly 
patients (more than 70 years of age) who were receiving mechanical ventilation, which reported 
lower albumin levels for non-survivors than survivors and concluded that low albumin level is an 
independent risk factor [54]. Finally, a meta-analysis that study hypoalbuminemia in acute illness 
concluded that this condition was a dose-dependent, “an independent risk factor for poor 
outcome in the acutely ill”, including mortality and morbidity [58]. Of note is that albumin 
testing is usually performed for specific diseases such as renal disease, but it is not as common as 
calcium and platelet counts in routine blood tests.  The albumin sample sizes in this study were 
smaller (between 10 and 18 units) than the sample sizes of the other parameters; the results 
suggest a correlation between low levels of albumin and mortality, but they are not conclusive 
and further studies will need to be conducted to analyze the influence of this parameter in clinical 
outcomes.     
The results for total carbon dioxide were similar than the results for albumin; no notable 
difference could be seen between survivors and non-survivors. Nevertheless, lower values of 
carbon dioxide were seen for non-survivors, causing probably imbalances in the patient’s 
electrolytes [44]. Total carbon dioxide is one of the parameters associated with acid-base 
imbalances, but to characterize these imbalances, usually other parameters are measured, such as 
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the anion gap or the pH, which measures the acidity or alkalinity in the blood. Low levels of total 
carbon dioxide result from either metabolic acidosis or as a compensation to respiratory alkalosis 
[59]. The ratios and the rates of change calculated with TCO2 could not differentiate survivors 
from non-survivors, and the predictive power of the models constructed was poor (c  0.54).   
The last parameter from the MIMIC II dataset analyzed was the anion gap. The results 
showed differences in mean and variability between survivors and non-survivors. Higher anion 
gaps (more than 16 mEq/L) and higher drops in anion gap were presented in non-survivors, 
which may be a signal of metabolic acidosis [60, 61] or any malfunction of the kidney or lungs. 
The ratios and rates of change for 1T  and 2T could differentiate survivors from non-survivors. 
However, as stated previously, anion gap is used with other parameters such as the total carbon 
dioxide, and the behaviors analyzed simultaneously have been shown to provide more 
information regarding acid-based disorders.  
There are studies that use a delta gap, which is the ratio of the variation in anion gap over 
the variation in bicarbonate, measured through the total carbon dioxide [62]. Further studies 
analyzing both parameters may provide more information, allowing a better understanding of 
these conditions and their impact in patient outcome.  
The performance of the models using each parameter independently was not better than 
the performance seen for platelet count, with the exception of albumin. In this case, the sample 
sizes were smaller (less than 18 values) than the sample sizes used for the other parameters. The 
best models were calcium ratios for 2T (c=0.56) and 3T (c=0.60), anion gap ratios for 1T (c=0.57) 
and 3T (c=0.56), TCO2 ratios for 2T (c=0.52) and 3T (c=0.55), and albumin ratios for 2T (c=0.64) 
and 3T (c=0.79).  
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 A multivariate analysis with different combinations of all parameters with ratios in 2T  
and 3T was conducted to evaluate if the results could be improved. Effectively, the addition of 
some parameters in the models improved the results in terms of concordance measures; however, 
the sample sizes were reduced in comparison to the sample sizes of individual parameters. When 
analyzing maximum likelihood estimates, some parameters are not significant in the models. 
The best model developed was the model that includes calcium, platelet count, and total 
carbon dioxide ratios for the intervals 2T (c=0.92) and 3T (c=0.76). It was observed that the 
combination of calcium, platelet count, and TCO2 improved the predictive power of the model. 
The sample sizes were reduced to 22 and 37 cases for 2r and 3r , respectively; however, the model 
parameters were statistically significant, with p-value=0.0021 for the likelihood ratio test. 
Therefore, the ratios for 2T may be used to simultaneously analyze changes over time in calcium, 
platelet count, and TCO2 and may be used as input for a predictive model, which could provide 
useful and prognostic information for care providers.   
Finally, interaction terms were added into the best models for ratios in the intervals 2T  
and 3T ; as a result, none of the interaction terms were significant, although in most of the cases 
the c-statistics were improved. All these results of applying models with several parameters 
suggest that the dynamism of the physiologic parameters studied could be captured through the 
metrics developed. However, further prospective studies should be conducted with bigger sample 
sizes to be conclusive and validate those models. The following chapter presents the conclusions 
derived from the previous discussion and the impact of the results in the patient monitoring 
process.   
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CHAPTER 5: CONCLUSIONS, LIMITATIONS AND FUTURE WORK 
 
The data mining approach has shown that the changes over time of specific physiologic 
parameters in critically-ill patients provide prognostic information and could aid physicians in 
their decision-making processes. Specific parameters such as platelet count, calcium, and anion 
gap have different behaviors or patterns in survivors and non-survivors.  A methodology was 
developed to simultaneously analyze important physiologic parameters in specific time intervals 
as short as four to six days after the second day of being admitted to an ICU. This method allows 
the stratification of retrospective patient care data under uncertain conditions of the specific 
diagnosis and the onset of the acute event, allowing predictive modeling with satisfactory 
accuracy to assist physicians in anticipating changes in recovery trajectories, allowing alterations 
in the patient management.  
Two methods of establishing rate of change (discrete point and regression on continuous 
data) were compared. Both metrics were comparable, differentiated survivors from non-
survivors, and, in homogeneous populations, were more predictive than more complex metrics 
and risk assessment scores with greater dimensionality. It also was demonstrated that the 
methodology could be applied to a heterogeneous population using changes over time in platelet 
count with satisfactory results, comparable to the results from the homogeneous dataset.  
Platelet count and calcium may provide prognostic information during the first 250 hours 
after ICU admission. Platelet count dropped below 150x109/L (common normal range) for the 
majority of the patients and then normalized or rose above this value during the first 200 hours.  
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A similar behavior was seen for calcium, but in this case the calcium for survivors stabilized 
during the first 150 hours, whereas non-survivors did not show a specific pattern.  
The use of calcium rates of change for a homogeneous population allowed the 
improvement of the predictive power of the regression models in 2T (c=0.79) and 3T (c=0.80). 
These results confirmed that calcium in blood (plasma calcium) is an important physiological 
marker to anticipate adverse events in critically-ill patients and should be included in any 
predictive model used for patient monitoring. Furthermore, combining mean platelet volume and 
platelet count as platelet mass, the results of the models using rates of change for 2T  (c=0.77) and 
3T  (c=0.78) were improved. However, mean platelet volume is not always included as part of a 
complete blood count test, and its use as a potential marker combined with platelet count should 
be analyzed considering other factors such as availability and cost.  It was demonstrated that the 
use of platelet mass and calcium rates of change for 2T , improves the performance of the 
predictive model (c=0.83).  
In a heterogeneous population, the rate of change determined by simpler fixed-time 
parameter value ratios applied to platelet count, calcium, albumin, anion gap, and total carbon 
dioxide was demonstrated to have better predictive power than the rate of change determined by 
multiple point regression. This situation should be due to the high variability of the data and 
heterogeneity of the population of the MIMIC II dataset. It was observed  that platelet count in 
the heterogeneous population was the best predictor of adverse outcomes among all the 
parameters evaluated. This result suggests that this parameter should be considered in critically-
ill patient monitoring processes during recovery trajectories.    
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The independent behavior of total carbon dioxide and albumin did not show notable 
differences between survivors and non-survivors. However, the anion gap showed differences 
between survivors and non-survivors in short time intervals (50 and 100 hours) after the first 50 
hours of ICU admission. The anion gap presented more variability for non-survivors and also 
greater values than the anion gap values for survivors. Therefore, in those models developed 
specifically for each parameter, the statistics associated with concordance measures were not 
sufficiently predictive. Nevertheless, the simultaneous analysis of two or more parameters 
improved the predictive power of those models, but reduced the sample sizes.  
The models developed for the heterogeneous population, including calcium, total carbon 
dioxide, and platelet count ratios for 2T and 3T , were more predictive (c=0.92) than models using 
complex metrics such as SOFA or APACHE II.  Nevertheless, the results are based on sample 
sizes that are smaller (18 N  82) than the sample sizes used for each parameter individually 
(192  N  533), with the exception of the albumin test (10 N  18), which is not conducted as 
frequently as the other tests.  The previous results suggest that the simultaneous use of simple 
ratios between two point values of the previous parameters in a short interval of four days may 
provide prognostic information.  
It was also observed that the inclusion of interaction terms in the classification models 
did not add any value to the results. Although in some cases, the c-statistics for the models were 
improved, the interactions between parameters were not significant in those models and, in other 
cases, no maximum likelihood estimates could be calculated due to the small sample size and 
because the data points were completely separated. This is evidence of the high variability 
presented in these complex physiologic parameters.   
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Being a retrospective study, the fact that interventions could not be implemented and 
assessed was an unavoidable limitation. Other limitations, specifically to the MIMIC II dataset, 
were the heterogeneity of the population, the differing stages of disease, and the variability 
regarding the recorded data, as it contains platelet measures registered before or after ICU 
admission and around 15% of the population had unknown ICU admission time and dates. In this 
case, the synchronization of the patient care cycle was not as simple as for the VA dataset, where 
the reference event for all patients was the date and time of surgery. For the MIMIC II data, it 
was assumed that the first platelet value and the minimum platelet value of the ICU patients were 
realistic surrogates for the time of the reference event or acute event, which may not be an 
accurate assumption in some cases. This critical assumption was substantiated by the results, 
which are comparable with the results from the homogeneous VA dataset.  This assumption was 
extended to other parameters: calcium, albumin, anion gap, and total CO2 and demonstrated that 
multivariate analysis, which includes hidden interactions between the parameters, improves the 
results considerably in terms of concordance measures (0.62  c  0.92).  Finally, considering 
the limitations associated with a retrospective study, a further prospective study is needed to 
validate the results to be applicable for new ICU patients. 
To summarize, the most relevant findings of this research are the following: 
• Changes over time of platelet count, calcium, anion gap, albumin, and total carbon 
dioxide in critically-ill patients may provide prognostic information. 
• Platelet count, calcium, and anion gap show different behaviors or patterns in 
survivors and non-survivors.   
• Rates of change in calcium in a homogeneous population provide a better 
classification model with more predictive power than platelet count.    
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• In a heterogeneous population, platelet count performed better as predictor of patient 
outcome than calcium, anion gap, albumin, and total carbon dioxide independently. 
• The combination of mean platelet volume with platelet count as platelet mass 
enhances the predictive power of the classification model. 
In conclusion, the most relevant contributions and impact of this research are the 
following: 
• The presented methodology could be generally applicable to ICUs and critically-ill 
patients, if at least two measures (ratio) or a small set of them (rate of change) of 
specific parameters in a short time frame (four to six days after two days of ICU 
admission or acute event) are available.  
• The metrics developed (ratios and rates of change) are comparable and they 
differentiate survivors from non-survivors and are more effective than complex 
metrics and risk assessment scores with greater dimensionality such as APACHE II 
and SOFA applied to a homogeneous population.  
• A new method of synchronization or alignment of the patient care cycle was 
provided. 
• The methodology is potentially extensible to other parameters with high levels of 
variation in short periods of time, providing an advantage over the classical use of 
times series when dealing with small sample sizes per patient.  
• This method allows the stratification of retrospective patient care data under uncertain 
conditions of the specific diagnosis and at the onset of an acute event, allowing 
predictive modeling with satisfactory accuracy to assist physicians in anticipating 
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changes in recovery trajectories, allowing alterations in patient management, and 
leading to more personalized patient care and reduced mortality rates.  
This research has contributed to the analysis of important and complex physiologic 
parameters, providing a methodology to analyze them and capture their dynamism through 
simple and proven metrics. However, there are still several unknown relationships among those 
physiologic parameters that need to be investigated. It also has been demonstrated that the 
changes over time of those parameters may provide prognostic information to care providers. 
Considering the high levels of mortality due to critical illnesses, it is important to continue 
working on a better understanding the behavior of those parameters to improve patient care.  
Future work research efforts should be focused on: 
• Combining parameters into a single metric. This may provide enhanced support to 
physicians with a simplified metric in anticipating potential adverse outcomes during 
the patient recovery process.  
• Stratifying patients by disease or by specific conditions to homogenize the population 
and improve the performance of the models, as was demonstrated by using the VA 
dataset. 
•  Investigating the behavior of anion gap and its relationship with total carbon dioxide, 
perhaps considering that the presence of fluid imbalances is a common disorder 
among ICU and critically-ill patients. Metabolic acidosis could be life-threatening, 
and this research and other studies suggest that both physiologic signals are correlated 
with increased mortality. 
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Appendix A Sensitivity Analysis with Bootstrapping - 100 Replicates 
 
Table A.1. Parameter estimates - PLT count in 53,2 ,, TTT  and 6T . Ratios ir , rates of change iRc  
Dataset Metric Sample size Parameter 
Estimate 
(regression 
model) 
Estimate 
(Bootstrapping) 
SD 
(Bootstrapping) 95%CI 
VA 
2r  180 
Intercept 1.33 1.27 1.01 [-0.35,3.90] 
PLT -2.21 -2.23 0.78 [-4.07,-1.07] 
3r  120 
Intercept 1.32 1.34 0.97 [-0.61,3.56] 
PLT -1.62 -1.65 0.57 [-2.94,-0.64] 
5r  180 
Intercept 2.12 2.14 1.15 [0.22,4.28] 
PLT -2.77 -2.79 0.83 [-4.68,-1.52] 
6r  180 
Intercept 1.19 1.22 1.09 [-0.94,3.59] 
PLT -1.59 -1.66 0.65 [-2.94,-0.51] 
2Rc  280 
Intercept -1.19 -1.20 0.32 [-1.81,-0.57] 
PLT -1.53 -1.53 0.43 [-2.34,-0.77] 
3Rc  340 
Intercept -0.88 -0.86 0.29 [-1.41,-0.30] 
PLT -1.63 -1.67 0.34 [-2.30,-1.18] 
5Rc  250 
Intercept -1.02 -1.00 0.33 [-1.67, -0.36] 
PLT -1.41 -1.43 0.36 [-2.37,-0.87] 
6Rc  250 
Intercept -0.70 -0.68 0.42 [-1.61,0.18] 
 PLT -1.56 -1.59 0.42 [-2.43,-0.92] 
MIMIC 
II 
2r  350 
Intercept -0.03 0.00 0.39 [-0.67,0.87] 
PLT -1.12 -1.14 0.34 [-1.85,-0.54] 
3r  250 
Intercept -0.40 -0.38 0.36 [-1.04,0.49] 
 PLT -0.64 -0.66 0.27 [-1.29,-0.21] 
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Appendix B Descriptive Statistics and p-values for the Differences in Mean  
 
Table B.1. MPV ir and iRc - VA dataset - Descriptive statistics. S, survivors; NS, non-survivors 
ir   1r   2r   3r  
  S NS  S NS  S NS 
Sample size  181 10  136 9  92 6 
Mean  0.9984 1.0110  0.9742 0.9755  0.9660 0.9633 
Standard Deviation  0.0662 0.0647  0.0812 0.0710  0.0920 0.1030 
p-value   0.571   0.959   0.953 
iRc   1Rc   2Rc   3Rc  
  S NS  S NS  S NS 
Sample size  239 14  244 14  247 14 
Mean  0.0007 -0.0082  -0.0034 -0.0044  -0.0037 -0.0028 
Standard Deviation  0.0162 0.0350  0.0099 0.0104  0.0088 0.0078 
p-value   0.361   0.731   0.638 
 
Table B.2. Ca ir and iRc - VA dataset - Descriptive statistics. S, survivors; NS, non-survivors 
ir   1r   2r   3r  
  S NS  S NS  S NS 
Sample size  184 10  136 10  86 7 
Mean  1.0346 1.0289  1.0625 1.0115  1.0552 0.9888 
Standard Deviation  0.0753 0.0660  0.0867 0.0978  0.0845 0.1023 
p-value   0.797   0.140   0.142 
iRc   1Rc   2Rc   3Rc  
  S NS  S NS  S NS 
Sample size  253 15  246 15  250 15 
Mean  0.0125 0.0058  0.0058 -0.0024  0.0054 -0.0016 
Standard Deviation  0.0353 0.0339  0.0081 0.0080  0.0071 0.0072 
p-value   0.451   0.002   0.002 
 
Table B.3. PLT mass ir and iRc - VA dataset - Descriptive statistics. S, survivors; NS, non-
survivors 
ir   1r   2r   3r  
  S NS  S NS  S NS 
Sample size  181 11  136 10  92 7 
Mean  1.2435 1.1225  1.649 1.2776  2.0035 1.3967 
Standard Deviation  0.3326 0.2857  0.5833 0.4720  0.9879 0.9300 
p-value   0.2008   0.038   0.142 
iRc   1Rc   2Rc   3Rc  
  S NS  S NS  S NS 
Sample size  241 15  245 15  249 15 
Mean  4.6521 -0.4699  6.9024 1.7796  7.8232 2.7541 
Standard Deviation  8.4409 10.8100  6.8900 4.1520  6.1226 3.7000 
p-value   0.092   0.000   0.000001 
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Table B.4. Ca ir and iRc - MIMIC II dataset - Descriptive statistics. S, survivors; NS, non-
survivors 
ir   1r   2r   3r  
  S NS  S NS  S NS 
Sample size  160 191  110 141  84 108 
Mean  1.0224 1.0189  1.027 1.0167  1.0432 1.022 
Standard Deviation  0.0679 0.0939  0.0865 0.114  0.0878 0.1124 
p-value   0.685   0.417   0.148 
iRc   1Rc   2Rc   3Rc  
  S NS  S NS  S NS 
Sample size  335 453  448 557  491 589 
Mean  0.0019 0.0023  0.0018 0.0039  0.0019 0.0037 
Standard Deviation  0.0280 0.0223  0.0119 0.0639  0.0097 0.0604 
p-value   0.851   0.480   0.489 
Table B.5. Albumin ir and iRc - MIMIC II dataset - Descriptive statistics. S, survivors; NS, non-
survivors 
ir   1r   2r   3r  
  S NS  S NS  S NS 
Sample size  6 12  3 11  6 4 
Mean  1.0178 1.0667  0.9376 0.8815  0.8635 1.0262 
Standard Deviation  0.2145 0.2893  0.1259 0.0787  0.1689 0.0974 
p-value   0.693   0.539   0.095 
iRc   1Rc   2Rc   3Rc  
  S NS  S NS  S NS 
Sample size  27 49  56 96  73 133 
Mean  -0.0046 -0.0021  -0.0047 -0.0015  -0.0029 -0.0012 
Standard Deviation  0.0337 0.0104  0.0213 0.0092  0.0191 0.0081 
p-value   0.71   0.275   0.47 
 
Table B.6. TCO2 ir and iRc - MIMIC II dataset - Descriptive statistics. S, survivors; NS, non-
survivors 
ir   1r   2r   3r  
  S NS  S NS  S NS 
Sample size  242 291  165 209  116 158 
Mean  1.0592 1.0468  1.1034 1.0856  1.1417 1.115 
Standard Deviation  0.1799 0.1769  0.19 0.1997  0.2472 0.2428 
p-value   0.425   0.38   0.374 
iRc   1Rc   2Rc   3Rc  
  S NS  S NS  S NS 
Sample size  596 655  634 691  641 693 
Mean  0.0198 0.0183  0.0165 0.0129  0.0144 0.0106 
Standard Deviation  0.1161 0.1375  0.0633 0.0742  0.0575 0.0678 
p-value   0.838   0.336   0.269 
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Table B.7. AG ir and iRc - MIMIC II dataset - Descriptive statistics. S, survivors; NS, non-
survivors 
ir   1r   2r   3r  
  S NS  S NS  S NS 
Sample size  213 257  145 195  104 136 
Mean  1.0504 0.9551  1.0096 0.9574  1.0322 0.9772 
Standard Deviation  0.2335 0.2303  0.2567 0.2326  0.2838 0.2759 
p-value   0   0.043   0.134 
iRc   1Rc   2Rc   3Rc  
  S NS  S NS  S NS 
Sample size  534 589  584 634  592 638 
Mean  0.0105 -0.0123  0.0027 -0.0061  0.003938 -0.0003 
Standard Deviation  0.1335 0.1228  0.0601 0.0870  0.05429 0.0723 
p-value   0.003   0.039   0.243 
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Appendix C Regression Models with Interaction Terms  
 
Table C.1. PLT mass and Ca 2r  - Regression model with interactions - VA dataset 
 Estimates Standard error 
Wald 
Chi-square 
Pr>Chi-
square 
Intercept -11.555 11.9707 0.9317 0.3344 
PLTmass 2r  13.063 12.1926 0.7601 0.3833 
Ca 2r  10.629 9.1305 2.0460 0.1526 
PLTmass 2r * Ca 2r  -13.880 9.2168 2.2680 0.1321 
c-statistic 0.773    
 
Table C.2. PLT mass and Ca 2Rc - Regression model with interactions - VA dataset 
 Estimates Standard error 
Wald 
Chi-square 
Pr>Chi-
square 
Intercept -2.044 0.3097 43.574 <.0001 
PLTmass 2Rc  -0.081 35.624 2.178 0.1399 
Ca 2Rc  -52.585 0.0428 3.621 0.0571 
PLTmass 2Rc * Ca 2Rc  -13.72 5.0494 7.389 0.0066 
c-statistic 0.867    
 
Table C.3. AG, Ca and TCO2 2r - Regression model with interactions - MIMIC II dataset 
 Estimates Standard error Wald Chi-square 
Pr>Chi-
square 
Intercept 65.996 123.0 0.288 0.5915 
AG 2r  -166.00 159.8 1.078 0.2991 
Ca 2r  -49.035 127.1 0.149 0.6997 
TCO2 2r  42.019 42.086 0.997 0.3181 
AG 2r * Ca 2r  152.4 155.0 0.966 0.3256 
AG 2r * TCO2 2r  -3.749 31.986 0.013 0.9067 
TCO2 2r * Ca 2r  -46.347 51.718 0.803 0.3702 
c-statistic 0.861    
 
Table C.4. Ca and TCO2 2r - Regression model with interactions - MIMIC II dataset 
 Estimates Standard error Wald Chi-square 
Pr>Chi-
square 
Intercept -58.722 45.615 1.657 0.1980 
Ca 2r  59.941 43.187 1.926 0.1652 
TCO2 2r  30.028 36.478 0.677 0.4104 
TCO2 2r * Ca 2r  -32.903 33.911 0.941 0.3319 
c-statistic 0.857    
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Appendix D Regression Models -Different Parameters - MIMIC II Dataset 
 
Table D.1. PLT and Ca ratios in 2T - Regression model 
Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -5.902 -  
PLT 2r  -0.351 0.704 [0.230, 2.151] 
Ca 2r  5.048 155.74 [0.466, >999.9] 
c-statistic 0.618   
 
Table D.2. PLT count and Ca ratios in 3T  - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -3.023 -  
PLT 3r  -0.287 0.751 [0.313, 1.795] 
Ca 3r  2.255 9.536 [0.014, >999.9] 
c-statistic 0.569   
 
Table D.3. PLT count and TCO2 ratios in 2T  - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 2.012 -  
PLT 2r  -1.034 0.356 [0.015,8.403] 
TCO2 2r  -2.186 0.112 [0.008,1.600] 
c-statistic 0.642   
 
Table D.4. PLT count and TCO2 ratios in 3T  - Regression model  
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -0.238 -  
PLT 3r  -0.232 0.793 [0.102, 6.158] 
TCO2 3r  -0.473 0.623 [0.316, 1.228] 
c-statistic 0.590   
 
Table D.5. AG and PLT count ratios in 2T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 1.015 -  
PLT 2r  -2.077 0.125 [0.016, 0.990] 
AG 2r  -0.323 0.724 [0.306, 1.711] 
c-statistic 0.633   
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Table D.6. AG and PLT count ratios in 3T  - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -0.056 -  
PLT 3r  -0.505 0.604 [0.080, 4.552] 
AG 3r  -0.505 0.603 [0.291,1.252] 
c-statistic 0.614   
 
Table D.7. Ca and TCO2 ratios in 2T  - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -16.483 -  
Ca 2r  20.381 >999.999 [1.158,>999.9] 
TCO2 2r  -5.363 0.005 [<0.001,3.505] 
c-statistic 0.848   
 
Table D.8. Ca and TCO2 ratios in 3T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -1.087 -  
Ca 3r  3.209 24.77 [<0.001, >999.9] 
TCO2 3r  -3.172 0.042 [<0.001,2.451] 
c-statistic 0.718   
 
Table D.9. AG and Ca ratios in 2T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -3.699 -  
Ca 2r  4.715 111.67 [0.100, >999.9] 
AG 2r  -2.385 0.092 [0.004, 2.309] 
c-statistic 0.671   
 
Table D.10. AG and Ca ratios in 3T  - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 1.988 -  
Ca 3r  -1.777 0.169 [<0.001, >999.9] 
AG 3r  -1.623 0.197 [0.004, 10.29] 
c-statistic 0.623   
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Table D.11. TCO2 and AG ratios in 2T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 2.077 -  
TCO2 2r  -0.115 0.891 [0.022, 36.82] 
AG 2r  -3.234 0.039 [<0.001,4.000] 
c-statistic 0.701   
 
Table D.12. TCO2 and AG ratios in 3T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 0.9887 -  
TCO2 3r  -0.436 0.646 [0.033, 12.575] 
AG 3r  -1.777 0.169 [0.008, 3.661] 
c-statistic 0.604   
 
Table D.13. PLT count, Ca and AG ratios in 2T - Regression model 
Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -4.338 -  
PLT 2r  0.594 1.813 [0.338, 9.730] 
Ca 2r  5.15 172.7 [0.139, >999.9] 
AG 2r  -2.93 0.053 [0.001, 1.976] 
c-statistic 0.662   
 
Table D.14. PLT count, Ca and AG ratios in in 3T  - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 2.727 -  
PLT 3r  -1.808 0.164 [0.013, 2.068] 
Ca 3r  -1.433 0.238 [<0.001, >999.9] 
AG 3r  -0.770 0.463 [0.007, 31.593] 
c-statistic 0.694   
 
Table D.15. PLT count, Ca and TCO2 ratios in 2T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -20.18 -  
PLT 2r  -6.228 0.002 [0.002,<0.001] 
Ca 2r  -30.936 >999.99 [46.774,>999.9] 
TCO2 2r  -7.313 <0.001 [<0.001,<0.001] 
c-statistic 0.924   
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Table D.16. PLT count, Ca and TCO2 ratios in 3T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -2.907 -  
PLT 3r  -1.707 0.181 [0.018, 1.877] 
Ca 3r  6.280 533.96 [0.005, >999.9] 
TCO2 3r  -2.596 0.075 [0.002, 3.632] 
c-statistic 0.765   
 
Table D.17. TCO2, Ca and AG ratios in 2T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -16.355 -  
Ca 2r  26.444 >999.9 [0.004,>999.9] 
TCO2 2r  -6.749 0.001 [<0.001,6.271] 
AG 2r  -5.618 0.004 [<0.001, 13.446] 
c-statistic 0.854   
 
Table D.18. TCO2, Ca and AG ratios in 3T  - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 5.493 -  
Ca 3r  -0.313 0.731 [<0.001, >999.9] 
TCO2 3r  -3.395 0.034 [<0.001, 24.69] 
AG 3r  -3.113 0.044 [<0.001, 12.298] 
c-statistic 0.715   
 
Table D.19. TCO2, AG and PLT count ratios in 2T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 3.460 -  
PLT 2r  -1.607 0.200 [0.008, 5.075] 
TCO2 2r  -0.269 0.764 [0.018,33.298] 
AG 2r  -3.111 0.045 [<0.001,5.535] 
c-statistic 0.707   
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Table D.20. TCO2, AG and PLT count ratios in 3T - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 1.4186 -  
PLT 3r  -0.4397 0.644 [0.282,1.464] 
TCO2 3r  -0.1834 0.832 [0.039, 17.808] 
AG 3r  -1.845 0.158 [0.007, 3.830] 
c-statistic 0.636   
 
Table D.21. PLT count, Ca, AG and TCO2 ratios in 2T  - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept -17.54 -  
PLT 2r  -5.597 0.004 [<0.001, 14.99] 
Ca 2r  31.360 >999.9 [0.755,>999.9] 
AG 2r  -3.856 0.021 [<0.001,140.75] 
TCO2 2r  -7.332 <0.001 [<0.001, 4.073] 
c-statistic 0.889   
 
Table D.22. PLT count, Ca, AG and TCO2 ratios in 3T  - Regression model 
  Odds ratio 
 Estimates Point estimate 95%CI 
Intercept 6.256 -  
PLT 3r  -2.351 0.095 [0.002, 5.288] 
Ca 3r  -1.726 0.178 [<0.001, >999.9] 
AG 3r  -2.039 0.130 [<0.001, 138.51] 
TCO2 3r  -1.518 0.219 [<0.001, 143.09] 
c-statistic 0.765   
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